Multiethnic genome-wide meta-analysis of ectopic fat depots identifies loci associated with adipocyte development and differentiation. by Chu, AY et al.
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Supplementary Table 1.  Nomenclature for fat traits and adjustment models. 2 
 3 
Abbreviation Trait Name 
Fat Volume Traits 
  SAT Subcutaneous adipose tissue volume 
  VAT Visceral adipose tissue volume 
  VATadjBMI Visceral adipose tissue volume adjusted for BMI 
  PAT Pericardial fat volume 
  PATadjHtWt Pericardial fat volume adjusted for height and weight 
Fat Attenuation Traits 
  SATHU Subcutaneous adipose tissue attenuation 
  VATHU Visceral adipose tissue attenuation 
Relative Fat Distribution Traits 
  VAT/SAT ratio Ratio of visceral to subcutaneous adipose tissue volume 
  VAT/SAT ratio adjBMI Ratio of visceral to subcutaneous adipose tissue volume adjusted for BMI 
 2
Supplementary Table 2a.  Ectopic fat assessment methods by cohort for subcutaneous and visceral adipose tissue. 4 
 5 
Cohort Modality Units 
Slice 
Number
Slice 
Thickness 
(mm) Level of image 
AGES CT cm2 1 10 L4-L5 
DHS CT cm3 4 2.5 L4-L5 
FamHS CT cm2 2 5 L4-L5 
FELS MRI cm3 24 10 T1-S1 
FHS CT cm3 25 5 125mm above S1 
GENOA CT cm3 24 2.5 L3-S1 
HABC CT cm2 1 10 L4-L5 
JHS CT cm3 24 2.5 L3-S1 
MESA CT cm2 2 6 L4-L5 
MRCOB CT cm3 3 3 L3 
PIVUS MRI cm2 1 10 L4-L5 
SHIP-2 MRI cm3 64 3-4 Whole abdomen 
SHIPTREND MRI cm3 64 3-4 Whole abdomen 
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Supplementary Table 2b.  Ectopic fat assessment methods by cohort for pericardial adipose tissue. 7 
 8 
Cohort Modality Units 
Slice 
Number
Slice 
Thickness 
(mm) Level of image 
Amish CT cm3 1 3 Full length of heart 
DHS CT cm3 18 2.5 
1.5cm and 3.0cm 
below superior 
extend of left main 
coronary artery 
FamHS CT cm3 18 2.5 
1.5cm and 3.0cm 
below superior 
extend of left main 
coronary artery 
FHS CT cm3 48 2.5 Full length of heart 
GENOA  cm3 1 45 Full length of heart 
MESA CT cm3 18 2.5 
1.5cm and 3.0cm 
below superior 
extend of left main 
coronary artery 
 4
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Supplementary Table 3a. Characteristics for cohorts contributing to subcutaneous adipose tissue volume (SAT) and visceral 10 
adipose tissue volume (VAT) analyses by strata (overall, women and men). 11 
Study Ancestry SAT VAT Women
Age  
(years) 
BMI  
(kg/m2) 
SAT  
(cm2 or *cm3) 
VAT  
(cm2 or *cm3) 
   N N % mean SD mean SD mean SD mean SD 
OVERALL   
AGES EA 3172 3172 57.8 76.4 5.4 27.1 4.4 257.6 113.2 172.7 80.7 
DHS* EA 445 448 53.5 62.1 9.3 31.8 6.5 708.6 313.4 442.6 174.7 
FamHS EA 2659 2659 55.3 57.2 13.3 28.8 5.7 286.0 132.0 167.0 91.0 
FELS* EA 578 578 52.6 44.7 17.8 26.8 5.7 4620.3 2970.3 2514.1 2046.6 
FHS* EA 3336 3336 48.2 52.8 11.8 27.8 5.2 2884.6 1389.8 1820.6 1033.3 
GENOA* AA 552 552 75.0 69.1 8.0 32.5 7.2 2319.8 985.6 906.0 392.8 
HABC AA 1041 1041 56.9 73.4 2.9 28.4 5.0 313.6 136.7 129.0 59.6 
HABC EA 1567 1567 47.1 73.8 2.8 26.6 4.1 266.3 101.9 153.4 69.5 
JHS* AA 1631 1631 63.8 59.3 10.9 31.8 6.4 2413.2 1026.6 837.3 382.6 
MESA AA 243 245 46.9 62.4 10.2 24.2 3.0 141.7 53.8 127.5 58.6 
MESA EA 664 744 49.3 62.8 9.8 27.8 4.8 208.3 98.8 176.4 92.0 
MRCOB* EA 423 423 59.8 42.9 15.8 32.6 8.8 84.9 47.8 48.4 30.3 
PIVUS EA 287 287 48.4 70.0 0.1 26.9 4.4 253.2 97.2 130.7 67.7 
SHIP-2* EA 783 783 35.9 52.9 12.1 27.3 3.9 7391.3 3078.7 4531.2 2311.2 
SHIPTREND* EA 866 866 56.1 50.3 13.5 27.2 4.3 7792.5 3394.3 3746.1 2321.2 
TOTAL  18247 18332  
   
WOMEN   
AGES EA 1835 1835 100.0 76.3 5.5 27.2 4.8 296.1 115.2 149.2 66.9 
DHS* EA 237 239 100.0 61.7 9.3 32.5 7.3 822.3 300.1 419.4 159.0 
FamHS EA 1189 1189 100.0 56.7 13.4 29.3 4.7 249.0 108.0 203.0 94.0 
FELS* EA 304 304 100.0 44.6 17.5 26.5 5.9 4932.9 3136.4 1687.5 1306.4 
FHS* EA 1608 1608 100.0 54.1 11.3 27.1 5.8 3149.9 1519.9 1367.1 833.2 
GENOA* AA 416 416 100.0 69.0 7.9 33.6 7.5 2586.5 916.0 894.3 382.2 
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Study Ancestry SAT VAT Women
Age  
(years) 
BMI  
(kg/m2) 
SAT  
(cm2 or *cm3) 
VAT  
(cm2 or *cm3) 
   N N % mean SD mean SD mean SD mean SD 
HABC AA 592 592 100.0 73.4 3.0 29.2 5.4 372.2 131.6 128.5 58.0 
HABC EA 739 739 100.0 73.7 2.8 26.1 4.4 311.3 104.9 134.3 62.0 
JHS* AA 1040 1040 100.0 59.7 10.9 32.9 6.9 2766.8 972.6 814.7 367.2 
MESA AA 115 115 100.0 62.4 9.7 24.3 3.2 165.3 48.4 111.6 48.1 
MESA EA 328 358 100.0 63.0 9.3 27.4 5.6 227.3 111.3 130.8 72.5 
MRCOB* EA 253 253 100.0 43.5 15.5 33.7 9.3 92.8 48.2 42.7 29.1 
PIVUS EA 139 139 100.0 70.0 0.1 26.9 4.8 286.6 106.3 110.2 58.3 
SHIP-2* EA 281 281 100.0 46.5 8.9 26.3 4.7 8622.3 3805.2 2455.8 1722.9 
SHIPTREND* EA 486 486 100.0 50.6 13.0 26.8 4.8 8794.8 3737.8 2684.5 1747.4 
TOTAL  9562 9594  
   
MEN   
AGES EA 1337 1337 0.0 76.5 5.3 26.9 3.8 204.6 85.8 205.1 86.5 
DHS* EA 208 209 0.0 62.5 9.3 30.9 5.4 579.1 276.4 469.0 188.1 
FamHS EA 1470 1470 0.0 57.6 13.1 28.5 6.3 315.0 142.0 138.0 78.0 
FELS* EA 274 274 0.0 44.7 18.2 27.2 5.4 4273.4 2738.5 3431.3 2313.8 
FHS* EA 1728 1728 0.0 51.5 12.2 28.5 4.5 2637.8 1205.7 2242.6 1022.8 
GENOA* AA 136 136 0.0 69.6 7.6 29.4 5.1 1505.2 704.8 941.7 423.2 
HABC AA 449 449 0.0 73.9 2.8 27.2 4.2 236.3 100.0 129.7 61.7 
HABC EA 828 828 0.0 73.9 2.9 27.1 3.7 226.1 80.1 170.3 71.6 
JHS* AA 591 591 0.0 58.5 10.8 29.8 4.9 1791.0 798.3 877.1 405.7 
MESA AA 128 130 0.0 62.5 10.7 24.2 2.9 120.5 49.7 141.6 63.5 
MESA EA 336 386 0.0 62.6 10.2 28.2 4.0 189.8 80.8 218.6 87.9 
MRCOB* EA 170 170 0.0 42.0 16.4 31.0 7.7 72.4 42.9 57.1 30.3 
PIVUS EA 148 148 0.0 70.0 0.1 26.8 3.9 221.8 87.8 150.0 75.5 
SHIP-2* EA 502 502 0.0 56.5 13.5 27.8 3.4 6702.3 2585.3 5693.0 2582.2 
SHIPTREND* EA 380 380 0.0 50.0 14.1 27.6 3.6 6510.5 2896.0 5103.8 2894.1 
TOTAL  8685 8738  
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Abbreviations: Please see Supplementary Table 9 for complete listing of cohort names and abbreviations 13 
 AA - African Ancestry; EA - European Ancestry 14 
 BMI - Body Mass Index 15 
 SAT - Subcutaneous Adipose Tissue Volume 16 
 VAT - Visceral Adipose Tissue Volume 17 
 N - Sample Size 18 
 SD - Standard Deviation 19 
 7
Supplementary Table 3b. Characteristics for cohorts contributing to pericardial adipose tissue volume (PAT) analysis 20 
Study Ancestry PAT Women
Age  
(years) 
BMI  
(kg/m2) 
PAT  
(cm2) 
    N % mean SD mean SD mean SD
OVERALL  
Amish EA 542 54.2 56.2 12.8 27.8 4.7 89.4 40.5
DHS EA 541 53.5 62.1 9.3 31.8 6.5 131.5 55.6
FamHS EA 892 52.8 62.7 11.3 29.1 5.5 82.4 43.9
FHS EA 3336 48.2 52.8 11.8 27.8 5.2 113.9 45.0
GENOA AA 552 75.0 69.1 8.0 32.5 7.2 66.2 27.6
MESA AA 1609 44.6 62.0 10.0 30.2 5.9 68.0 34.9
MESA AS 768 51.0 62.4 10.4 24.0 3.3 74.1 31.6
MESA EA 2519 52.6 62.8 10.1 27.7 5.1 85.4 46.1
MESA HS 1445 52.0 61.4 10.3 29.4 5.1 88.6 43.7
TOTAL   12204        
  
WOMEN  
Amish EA 294 100.0 55.8 12.3 28.7 5.4 86.1 36.3
DHS EA 302 100.0 61.7 9.3 32.5 7.3 117.9 45.1
FamHS EA 421 0.0 64.7 10.0 28.7 6.1 97.0 51.1
FHS EA 1608 100.0 54.1 11.3 27.1 5.8 101.2 39.0
GENOA AA 416 100.0 69.0 7.9 33.6 7.5 64.8 26.4
MESA AA 868 100.0 62.0 9.9 31.4 6.5 61.5 29.2
MESA AS 390 100.0 60.8 10.1 23.9 3.5 70.0 20.6
MESA EA 1317 100.0 62.7 10.3 27.5 5.8 70.5 34.8
MESA HS 746 100.0 60.7 10.3 29.5 5.4 76.0 35.4
TOTAL   6362        
  
MEN  
Amish EA 248 0.0 56.6 13.3 26.7 3.5 93.2 44.7
DHS EA 239 0.0 62.5 9.3 30.9 5.4 148.6 62.5
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Study Ancestry PAT Women
Age  
(years) 
BMI  
(kg/m2) 
PAT  
(cm2) 
FamHS EA 471 100.0 60.5 12.3 29.6 4.7 69.4 30.8
FHS EA 1728 0.0 51.5 12.2 28.5 4.5 125.8 46.9
GENOA AA 136 0.0 69.6 7.6 29.4 5.1 70.6 30.6
MESA AA 741 0.0 62.1 10.2 28.8 4.8 76.0 39.5
MESA AS 378 0.0 61.6 10.3 24.1 3.1 78.0 35.0
MESA EA 1202 0.0 62.9 10.0 27.9 4.1 101.8 51.2
MESA HS 699 0.0 60.4 10.3 28.6 4.1 101.0 47.7
TOTAL 5842
Abbreviations: Please see Supplementary Table 9 for complete listing of cohort names and abbreviations 21 
 AA - African Ancestry; AS - Chinese Ancestry; EA - European Ancestry; HS - Hispanic Ancestry 22 
 BMI - Body Mass Index 23 
 PAT - Pericardial Adipose Tissue Volume 24 
 N - Sample Size 25 
 SD - Standard Deviation 26 
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Supplementary Table 3c.  Characteristics for cohorts contributing to subcutaneous and visceral adipose tissue attenuation (SATHU 27 
and VATHU) analyses 28 
Study Ancestry SATHU VATHU
SAT HU  
(HU) 
VAT HU  
(HU) 
   N N mean SD mean SD
OVERALL  
AGES EA 3172 3172 -99.0 5.9 -86.2 7.3
FamHS EA 2659 2659 -101.5 6.5 -92.9 8.0
FHS EA 3336 3336 -100.9 5.0 -93.9 4.6
HABC AA 1041 1041 -97.2 10.7 -85.3 10.3
HABC EA 1567 1567 -96.9 8.1 -88.3 9.2
MESA EA 664 744 -92.8 9.9 -62.8 23.2
TOTAL   12439 12519     
          
WOMEN  
AGES EA 1835 1835 -100.6 5.3 -85.7 7.4
FamHS EA 1189 1189 -99.6 5.9 -95.0 6.9
FHS EA 1608 1608 -102.3 5.1 -92.5 4.4
HABC AA 592 592 -100.6 8.1 -87.2 8.6
HABC EA 739 739 -100.5 7.4 -88.4 9.6
MESA EA 328 358 -96.7 8.7 -57.9 25.2
TOTAL   6291 6321     
          
MEN  
AGES EA 1337 1337 -96.7 5.9 -87.0 7.2
FamHS EA 1470 1470 -103.1 6.5 -91.2 8.4
FHS EA 1728 1728 -99.6 4.4 -95.2 4.5
HABC AA 449 449 -92.7 10.7 -82.8 11.6
HABC EA 828 828 -93.7 7.4 -88.2 8.8
MESA EA 336 386 -89.0 9.6 -67.4 20.2
TOTAL 6149 6199
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Abbreviations: Please see Supplementary Table 9 for complete listing of cohort names and abbreviations 29 
 AA - African Ancestry; EA - European Ancestry 30 
 BMI - Body Mass Index 31 
 SATHU - Subcutaneous Adipose Tissue Attenuation 32 
 VATHU - Visceral Adipose Tissue Attenuation 33 
 HU - Hounsfield Units 34 
 N - Sample Size 35 
 SD - Standard Deviation 36 
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Supplementary Table 3d. Characteristics for cohorts contributing to ratio of visceral to subcutaneous adipose tissue volume ratio 37 
(VAT/SAT ratio) analysis 38 
Study Ancestry 
VAT/SAT 
ratio Women VAT/SAT ratio 
    N % mean SD
OVERALL  
AGES EA 3172 57.8 0.8 0.4
DHS EA 433 53.5 0.7 0.4
FamHS EA 2658 55.3 0.7 0.4
FELS EA 578 52.6 0.6 0.4
FHS EA 3158 48.2 0.7 0.4
GENOA AA 552 75.0 0.4 0.2
HABC AA 1039 56.9 0.5 0.3
HABC EA 1567 47.1 0.6 0.3
JHS AA 1621 63.8 0.4 0.2
MESA AA 317 46.9 1.0 0.5
MESA EA 662 49.3 0.9 0.5
MRCOB EA 412 59.8 0.7 0.4
PIVUS EA 373 48.4 0.6 0.2
SHIP-2 EA 783 35.9 0.7 0.1
SHIPTREND EA 866 56.1 0.5 0.1
TOTAL   18191    
  
WOMEN  
AGES EA 1835 100.0 0.5 0.3
DHS EA 229 100.0 0.5 0.2
FamHS EA 1469 100.0 0.5 0.3
FELS EA 304 100.0 0.3 0.2
FHS EA 1516 100.0 0.4 0.2
GENOA AA 416 100.0 0.4 0.2
HABC AA 591 100.0 0.4 0.2
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Study Ancestry 
VAT/SAT 
ratio Women VAT/SAT ratio 
    N % mean SD
HABC EA 739 100.0 0.5 0.2
JHS AA 1031 100.0 0.3 0.1
MESA AA 167 100.0 0.7 0.2
MESA EA 326 100.0 0.6 0.3
MRCOB EA 253 100.0 0.5 0.3
PIVUS EA 180 100.0 0.4 0.2
SHIP-2 EA 281 100.0 0.3 0.1
SHIPTREND EA 486 100.0 0.3 0.1
TOTAL 9823
  
MEN  
AGES EA 1337 0.0 1.1 0.4
DHS EA 204 0.0 0.9 0.4
FamHS EA 1189 0.0 0.9 0.4
FELS EA 274 0.0 0.8 0.4
FHS EA 1642 0.0 0.9 0.4
GENOA AA 136 0.0 0.7 0.3
HABC AA 448 0.0 0.6 0.3
HABC EA 828 0.0 0.8 0.3
JHS AA 590 0.0 0.5 0.2
MESA AA 150 0.0 1.2 0.5
MESA EA 336 0.0 1.2 0.5
MRCOB EA 165 0.0 0.9 0.5
PIVUS EA 193 0.0 0.7 0.3
SHIP-2 EA 502 0.0 0.9 0.3
SHIPTREND EA 380 0.0 0.8 0.3
TOTAL   8374    
Abbreviations: Please see Supplementary Table 9 for complete listing of cohort names and abbreviations 39 
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 AA - African Ancestry; EA - European Ancestry 40 
 BMI - Body Mass Index 41 
 SAT - Subcutaneous Adipose Tissue Volume 42 
 VAT - Visceral Adipose Tissue Volume 43 
 VAT/SAT ratio - Visceral to Subcutaneous Adipose Tissue Volume Ratio 44 
 N - Sample Size 45 
 SD - Standard Deviation 46 
  47 
 48 
49 
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Supplementary Table 4.  Cohort Genotyping Information 51 
Study Array type Genotype 
calling 
Quality 
control 
filters for 
genotyped 
SNPs used 
for 
imputation 
No of SNPs 
used for 
imputation 
Imputation Imputation 
Backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering 
of imputed 
genotypes 
Data 
management 
and 
statistical 
analysis 
AGES Illumina 
Hu370CNV 
Illumina 
BeadStudio 
call rate 
<97%; 
genotype 
sex 
mismatch: 
mismatch 
previous 
genotypes 
324,603 MACH+Mini
Mac 
HapMap 
release 22 
(build 36) 
none R, PLINK, 
ProbABEL 
Amish Affymetrix 
500K, 
Affymetric 
6.0 
Affymetrix SNP call 
rate >95%, 
MAF >0, 
and HWE 
(at 
P>0.0001) 
373,825 MACH 
version 
1.0.15 
HapMap 
release 22 
(build 36) 
none Mixed Model 
Analysis in 
Pedigrees  
(MMAP) 
DHS Genome-
Wide 
Human 
SNP Array 
5.0 
Affymetrix call rate > 
0.95, 
HWE_pval 
>0.0001, 
MAF>0.01 
361,574 IMPUTE 
v2.2.2 
HapMap 
release 22 
(build 36) 
none SOLAR 
FamHS Illumina 
550K, 
Illumina 
610K, and 
Illumina 1M 
BeadStudio-
GenCall 
v3.0 
MAF <1% 
or >99%; 
p≤10-6; 
callrate 
<98% 
824,714 MACH 
version 
1.0.16 
HapMap 
release 22 
(build 36) 
none R mixed 
model with 
kinship matrix 
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Study Array type Genotype 
calling 
Quality 
control 
filters for 
genotyped 
SNPs used 
for 
imputation 
No of SNPs 
used for 
imputation 
Imputation Imputation 
Backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering 
of imputed 
genotypes 
Data 
management 
and 
statistical 
analysis 
FELS Illumina 
Human 
610 Quad 
v1_B 
Illumina's 
GenomeStu
dio (v1.5.16)
pHWE<1e-
6, call 
rate<90%, 
MAF<0.01, 
Mendelian 
errors 
(Simwalk) 
542,711 MACH 
version 1.0 
HapMap 
release 21 
(build 35) 
none Pedsys, R, 
SOLAR 
FHS Affymetrix 
500K 
Affymetrix 
50K 
supplemen
tal 
Affymetrix pHWE<1e-
6, call 
rate<97%, 
mishap (non 
random 
missingness 
by 
haplotype) 
p<1e-9, 
MAF<0.01, 
Mendelian 
errors>100, 
SNPs not in 
Hapmap or 
strandednes
s issues 
merging 
with 
Hapmap 
378,163 MACH 
version 
1.0.15 
HapMap 
release 22 
(build 36) 
none R, linear 
mixed effect 
models and 
GEE models, 
robust 
variance 
option to 
account for 
relatedness 
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Study Array type Genotype 
calling 
Quality 
control 
filters for 
genotyped 
SNPs used 
for 
imputation 
No of SNPs 
used for 
imputation 
Imputation Imputation 
Backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering 
of imputed 
genotypes 
Data 
management 
and 
statistical 
analysis 
GENOA Affymetrix 
6.0 & 
Illumina 1M 
Birdseed & 
GenomeStu
dio 
call rate < 
95%; 
MAF<0.01; 
SNPs not in 
HapMap 
Affymetrix 
6.0: 550,325 
Illumina 1M: 
780,147 
ARIC 
Affymetrix 
6.0: 565,043
MACH 
1.0.16 
HapMap 
release 22 
(build 36); 
combined 
CEU+YRI 
reference 
panel 
none MMAP 
HABC 
(European 
Ancestry) 
Illumina 
Human 
1M-Duo 
BeadChip 
BeadStudio 
version 
3.3.7 
SNPs with 
minor allele 
frequency ≥ 
1%, call rate 
≥97% and 
HWE p≥10-
6 were used 
for 
imputation. 
914,263 MACH HapMap 
release 22 
(build 36) 
none R 
HABC 
(African 
Ancestry) 
Illumina 
Human 
1M-Duo 
BeadChip 
BeadStudio 
version 
3.3.7 
SNPs with 
minor allele 
frequency ≥ 
1%, call rate 
≥97% and 
HWE p≥10-
6 were used 
for 
imputation. 
1,007,948 MACH HapMap 
release 22 
(build 36) 
none R 
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Study Array type Genotype 
calling 
Quality 
control 
filters for 
genotyped 
SNPs used 
for 
imputation 
No of SNPs 
used for 
imputation 
Imputation Imputation 
Backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering 
of imputed 
genotypes 
Data 
management 
and 
statistical 
analysis 
JHS Affymetrix 
Genome-
Wide 
Human 
SNP Array 
6.0 
Birdseed 
v1.33 
SNP level 
callrate > 
90%, 
sample level 
callrate 
>95%, MAF 
>0.01, HWE 
> 1E-06 
832,508 MACH and 
Minimac 
HapMap 
release 22 
(build 36) 
none MACH2QTL 
MESA Affymetrix 
Genome-
Wide 
Human 
SNP Array 
6.0 
Affymetrix pHWE<1e-
6, call 
rate<95%, 
MAF<0.01, 
888,666 IMPUTE2 HapMap 
release 22 
(build 36) 
none SAS, 
SNPTEST2, 
R 
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Study Array type Genotype 
calling 
Quality 
control 
filters for 
genotyped 
SNPs used 
for 
imputation 
No of SNPs 
used for 
imputation 
Imputation Imputation 
Backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering 
of imputed 
genotypes 
Data 
management 
and 
statistical 
analysis 
MRCOB/ 
TOPS 
Affymetrix 
Genome-
Wide 
Human 
SNP 6.0 
arrays 
Affymetrix 
50K 
supplemen
tal 
Genotype 
Console 3.2 
pHWE<1e-
8, call 
rate<95%, 
>2 alleles 
called, 
fewer than 5 
copies of 
minor allele, 
SNPs not in 
Hapmap or 
strandednes
s issues 
merging 
with 
Hapmap 
869,222 Impute2/SH
APEIT/MER
LIN 
HapMap 
release 22 
(build 36) 
none SOLAR, 
variance 
components 
models 
including 
random effect 
of kinship 
PIVUS Human 
Omni 
Express 
and 
Metabochi
p 
Illumina For SNPs 
with MAF 
>=0.05: 
pHWE<1e-
6, call 
rate<95%; 
For SNPs 
with MAF 
<0.05: 
pHWE<1e-
6, call 
rate<99%; 
MAF<0.01 
738,879 IMPUTE 
version 
2.1.2 
HapMap 
release 22 
(build 36) 
none SNPTEST 
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Study Array type Genotype 
calling 
Quality 
control 
filters for 
genotyped 
SNPs used 
for 
imputation 
No of SNPs 
used for 
imputation 
Imputation Imputation 
Backbone 
for phased 
CEU 
haplotypes 
(NCBI build) 
Filtering 
of imputed 
genotypes 
Data 
management 
and 
statistical 
analysis 
SHIP-2 Affymetrix 
Genome-
Wide 
Human 
SNP Array 
6.0 
Birdseed2 none 869,224 IMPUTE 
v0.5.0 
HapMap 
release 22 
(build 36) 
none quicktest 
v0.95 
SHIP-
TREND 
Illumina 
Omni 2.5 
GenCall pHWE <= 
0.0001 or 
CallRate <= 
0.9 or 
monomorphi
c SNPs 
1,782,967 IMPUTE 
v2.1.2.3 
HapMap 
release 22 
(build 36) 
none quicktest 
v0.95 
 52 
 53 
 54 
 55 
56 
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Supplementary Table 5.  Heritability estimates of ectopic fat traits in the Framingham Heart Study in the overall cohort (N=3,312) 57 
and stratified by sex (NWOMEN=1,593 and NMEN=1,719).  Heritability estimates were calculated using variance components estimation 58 
in SOLAR1. 59 
  ALL WOMEN MEN 
TRAIT N H2r P SE N H2r P SE N H2r P SE 
SAT 3312  0.59* 6.4E-55 0.04 1593 0.64 8.8E-22 0.07 1719   0.71# 2.3E-26 0.07 
SATHU 3312  0.29# 7.6E-17 0.04 1593   0.30# 2.8E-06 0.07 1719   0.40# 2.6E-12 0.07 
VAT 3312 0.39 1.5E-32 0.04 1593  0.55* 1.9E-16 0.07 1719 0.51 5.5E-17 0.07 
VATHU 3312 0.31 9.9E-19 0.04 1593 0.38 5.9E-09 0.07 1719 0.39 5.5E-10 0.07 
VAT/SAT ratio 3312 0.55 6.0E-54 0.04 1593 0.55 8.6E-16 0.07 1719 0.61 1.0E-22 0.07 
VAT/SAT ratio 
adjBMI 3299 0.55 5.2E-05 0.04 1584 0.56 3.9E-16 0.07 1715 0.59 4.9E-21 0.07 
 60 
* Kurtosis is moderate 61 
# Kurtosis is very high 62 
  63 
Abbreviations:   64 
N - Sample Size 65 
 H2r - Heritability 66 
 P - P-value 67 
 SE - Standard Error 68 
 SAT - Subcutaneous Adipose Tissue Volume 69 
 SATHU - Subcutaneous Adipose Tissue Attenuation 70 
 VAT - Visceral Adipose Tissue Volume 71 
 VATHU - Visceral Adipose Tissue Attenuation 72 
 VAT/SAT ratio - Visceral to Subcutaneous Adipose Tissue Volume Ratio 73 
 adjBMI - Adjusted for Body Mass Index 74 
 75 
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Supplementary Table 6.  Pairwise genetic correlations between ectopic fat depots and body mass index (BMI) among 3,336 76 
participants from the Framingham Heart Study.  Bottom diagonal is the genetic correlation (RhoG) between traits with P-value testing 77 
for overlapping genetic correlations (RhoG = 0), and the top diagonal is the P-value testing for non-overlapping genetic correlations 78 
(absolute value [RhoG ]= 1). 79 
  80 
  Non-overlapping genetic correlation, P (abs(RhoG)=1) 
 SAT SATHU VAT VATHU VAT/SAT ratio BMI 
Genetic 
correlation 
estimate 
(RhoG),  
P (RhoG=0) 
SAT -- P=1.0E-9 P=1.7E-28 P=3.6E-17 P=2.6E-32 P=6.7E-40 
SATHU -0.54, P=9.4E-10 -- P=1.2e=11 P=4.5E-11 P=4.2E-11 P=1.8E-11 
VAT 0.67, P=3.7E-24 -0.35, P=3.2E-4 -- P=2.0E-14 P=2.8E-35 P=5.3E-23 
VATHU -0.40, P=5.9E-7 0.52, P=6.3E-6 -0.74, P=4.7E-16 -- P=1.4E-16 P=9.8E-16 
VAT/SAT ratio -0.43, P=1.9E-12 0.21, P=0.019 0.35, P=4.7E-7 -0.41, P=6.0E-7 -- P=3.2E-37 
BMI 0.87, P=2.5E-42 -0.27, P=2.5E-3 0.76, P=3.8E-28 -0.45, P=2.6E-8 -0.19, P=3.9E-4 -- 
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Supplementary Table 7.   Pearson correlation coefficients for ectopic fat traits in the 81 
Framingham Heart Study.2-5 Correlation coefficients for women in gray and men in white. 82 
83 
  MEN 
  
 SAT SATHU VAT VATHU 
VAT/SAT 
ratio BMI 
WOMEN SAT 
 -- -0.56 0.58 -0.40 -0.43 0.83 
SATHU 
 -0.49 -- -0.42 NA 0.17 -0.34 
VAT 
 0.71 -0.36 -- -0.72 0.42 0.71 
VATHU 
 -0.51 NA -0.75 -- -0.38 -0.42 
VAT/SAT 
ratio -0.11 0.04 0.53 -0.49 -- -0.14 
BMI 0.88 -0.30 0.75 -0.51 0.06 -- 
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Supplementary Table 8a.  Imputation quality for UBE2E2, RREB1, ATXN1, GRAMD3 and 84 
GSDMB by cohort 85 
Cohort Ancestry rs7374732 (UBE2E2) 
rs2842895 
(RREB1) 
rs2237199 
(ATXN1) 
rs10060123 
(GRAMD3) 
rs2123685 
(GSDMB) 
AGES EU 1.00 0.93 0.99 0.92 0.99 
DHS EU 1.00 NA 0.90 NA 0.99 
FamHS EU 1.00 0.94 1.00 0.95 0.97 
FELS EU 1.00 0.94 NA 0.96 0.97 
FHS EU 0.97 0.94 0.89 0.96 0.99 
GENOA AF 1.00 NA NA 0.92 NA 
HABC AF 1.00 0.94 0.98 0.98 1.00 
HABC EU 1.00 0.95 1.00 0.97 0.97 
JHS1 AF 1.00 0.92 NA 0.94 NA 
JHS2 AF 1.00 0.92 NA 0.96 NA 
MESA AF 1.00 0.91 0.82 0.95 NA 
MESA EU 1.00 0.87 0.87 0.93 0.98 
MRCOB EU 0.96 0.88 NA 0.97 1.19 
PIVUS EU 1.00 0.88 NA 0.95 0.98 
SHIP2 EU 1.00 0.88 NA 0.95 1.19 
SHIP-TREND EU 1.00 0.95 NA 0.95 1.19 
Ancestry abbreviations: EA - European ancestry, AA - African ancestry, AS - Asian ancestry, 86 
HS - Hispanic ancestry 87 
 88 
89 
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Supplementary Table 8b.  Imputation quality for EBF1 and ENSA by cohort. 90 
Cohort Ancestry rs1650505 (EBF1) 
rs6587515 
(ENSA) 
Amish EU 0.85 0.99 
DHS EU 0.97 0.97 
FamHS EU 1.00 1.00 
FHS EU 0.95 1.01 
MESA EU 0.96 0.99 
GENOA AF 0.85 NA 
MESA AF 1.00 0.94 
MESA AS 0.99 1.01 
MESA HS 0.97 0.97 
 91 
Ancestry abbreviations: EA - European ancestry, AF - African ancestry, AS - Asian ancestry, 92 
HS - Hispanic ancestry  93 
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Supplementary Table 9.  Ancestry-specific association results of lead SNPs from newly identified ectopic fat loci from a sample size 94 
weighted fixed effects meta-analysis implemented in METAL.6,7 95 
Locus1 Traits Strata Ancestry2 Lead SNP A13 A24 FreqA15 N Z score P-value6 
Fat Volume Traits8 
ENSA PATadjHtWt ALL 
EU 
rs6587515 a g 
0.10 7425 -5.00 4.8E-07 
AF 0.02 1442 -1.30 1.9E-01 
AS 0.20 761 -2.80 5.9E-03 
HS 0.06 1399 -1.70 8.5E-02 
GRAMD3 VATadjBMI WOMEN 
EU 
rs10060123 a c 
0.26 7403 4.80 1.3E-06 
AF 0.14 2220 2.60 1.1E-02 
EBF1 PATadjHtWt ALL 
EU 
rs1650505 a g 
0.22 7412 -4.50 6.7E-06 
AF 0.22 1994 -3.40 7.8E-04 
AS 0.31 761 -2.30 2.3E-02 
HS 0.29 1399 -1.50 1.3E-01 
RREB1 VATadjBMI ALL 
EU 
rs2842895 c g 
0.58 14295 5.80 5.8E-09 
AF 0.11 3002 1.00 3.0E-01 
GSDMB7 SAT WOMEN EU rs2123685 t c 0.94 7137 5.52 3.4E-08 
Fat Quality Traits8 
ATXN1 SATHU MEN 
EU 
rs2237199 a g 
0.11 5331 5.30 1.4E-07 
AF 0.11 449 2.20 2.8E-02 
Relative Fat Distribution Traits8 
UBE2E2 VAT/SAT ratio ALL 
EU 
rs7374732 t c 
0.63 14674 -5.10 2.9E-07 
AF 0.90 3531 -3.80 1.3E-04 
1 Conventional locus name based on closest gene in the region 96 
2 Ancestry abbreviations: EU - European ancestry, AF - African ancestry, AS - Asian ancestry, HS - Hispanic ancestry 97 
3 A1 is the coded allele 98 
4 A2 is the non-coded allele 99 
5 FreqA1 is the allele frequency of the coded allele 100 
6 P-values are double GC corrected 101 
7 rs2123685 near GSDMB was observed only in European ancestry cohorts and therefore the multiethnic meta-analyses reflect the 102 
ancestry-specifc meta-analysis 103 
 26
8 European and African ancestry cohorts contributed to all ectopic fat traits; Chinese and Hispanic ancestry cohorts contributed only 104 
to pericardial volume traits. 105 
Abbreviations: 106 
 N - Sample Size 107 
PATadjHtWt - Pericardial Adipose Tissue Volume Adjusted for Height and Weight 108 
VATadjBMI - Visceral Adipose Tissue Volume Adjusted for Body Mass Index 109 
SAT - Subcutaneous Adipose Tissue Volume 110 
SATHU - Subcutaneous Adipose Tissue Attenuation 111 
VAT/SAT ratio - Visceral to Subcutaneous Adipose Tissue Volume Ratio112 
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Supplementary Table 10.  Association of newly identified loci with other ectopic fat 113 
traits within VATGen* (using the sample size weighted fixed effects meta-analysis 114 
method implemented in METAL6,7) and with BMI and WHR from the GIANT 115 
Consoritum.8,9  116 
 117 
A. GSDMB 118 
  Trait Strata Direction P-value N 
VATGen 
SAT 
ALL + 9.5E-06 14230 
WOMEN + 3.4E-08 7137 
MEN + 0.61 6681 
VAT WOMEN + 4.8E-04 7167 
VATSAT WOMEN - 0.17 7136 
GIANT 
BMI WOMEN + 2.0E-03 131549 
WHRadjBMI WOMEN - 0.75 86317 
 119 
B. RREB1 120 
  Trait Strata 
Directio
n P-value N 
VATGen 
VATadjBMI 
ALL + 1.1E-08 17297 
WOMEN + 1.8E-03 9207 
MEN + 1.5E-06 8090 
VAT ALL + 4.8E-05 17312 
SAT ALL + 0.87 17209 
VATSATadjBMI ALL + 8.9E-06 17193 
GIANT BMI ALL + 0.01 235260 
WHRadjBMI ALL + 1.4E-04 142019 
 121 
 122 
C. GRAMD3 123 
  Trait Strata Direction P-value N 
VATGen 
VATadjBMI 
ALL + 2.2E-04 17849 
WOMEN + 4.5E-08 9623 
MEN - 0.85 8226 
VAT WOMEN + 1.1E-06 9634 
SAT WOMEN + 0.11 9590 
VATSATadjBMI WOMEN + 3.2E-04 9578 
GIANT 
BMI WOMEN + 0.43 131761 
WHRadjBMI WOMEN + 0.66 85564 
 124 
D. EBF1 125 
  Trait Strata Direction P-value N 
VATGen 
PATadjHtWt 
ALL - 1.0E-09 11566 
WOMEN - 1.8E-07 6101 
MEN - 1.0E-04 5465 
SAT ALL + 0.06 16576 
VAT ALL + 0.98 16682 
VATSAT ALL - 0.09 16575 
GIANT 
BMI ALL - 0.33 236156 
WHRadjBMI ALL + 0.88 142655 
 126 
 28
 127 
 128 
 129 
 130 
E. ENSA 131 
  Trait Strata Direction P-value N 
VATGen 
PATadjHtWt 
ALL - 2.8E-09 11027 
WOMEN - 4.0E-06 5691 
MEN - 2.0E-05 5336 
SAT ALL + 0.05 15264 
VAT ALL + 0.21 15347 
VATSAT ALL + 0.68 15263 
GIANT 
BMI ALL + 0.13 236166 
WHRadjBMI ALL - 0.33 142737 
 132 
F. ATXN1 133 
  Trait Strata Direction P-value N 
VATGen 
SATHU 
ALL + 1.9E-03 12255 
WOMEN - 0.36 6475 
MEN + 1.4E-08 5780 
VATHU Men + 8.0E-06 5830 
SAT Men - 3.9E-04 7771 
VAT Men - 2.7E-03 7831 
GIANT BMI Men + 0.96 99228 
WHRadjBMI Men + 0.65 51038 
 134 
G. UBE2E2 135 
  Trait Strata Direction P-value N 
VATGen 
VATSAT 
ALL - 3.1E-10 18205 
WOMEN - 5.8E-08 9826 
MEN - 8.8E-04 8379 
VATSATadjBMI ALL - 1.7E-08 18190 
VAT ALL - 1.4E-03 18312 
SAT ALL + 0.32 18206 
GIANT 
BMI ALL + 0.83 236146 
WHRadjBMI ALL - 0.04 142752 
 136 
* The trait and strata in which the locus was originally identified in is bolded. 137 
Abbreviations 138 
 N - Sample Size 139 
SAT - Subcutanous Adipose Tissue Volume 140 
 VAT - Visceral Adipose Tissue Volume 141 
 BMI - Body Mass Index 142 
 WHR - Waist to Hip Ratio 143 
 adjBMI - Adjusted for BMI 144 
 SATHU - Subcutaneous Adipose Tissue Attenuation 145 
 VATHU - Visceral Adipose Tissue Attenuation 146 
 PAT - Pericardial Adipose Tissue Volume 147 
 adjHtWt - Adjusted for Height and Weight  148 
 149 
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Supplementary Table 11. Summary of direction concordant associations for 97 body mass index (BMI - top) and 49 waist-hip ratio 150 
(WHR - bottom) GWAS SNPs in association with listed ectopic fat traits.  Direction consistent indicates the number of SNPs with an 151 
effect estimate that is concordant with Locke et al.9 and Shungin et al.8 for all SNPs. SAT was the only trait with a significant number 152 
of concordant associations for BMI, and thus was evaluated for only those associations attaining nominal significance for ectopic fat 153 
(PSAT<0.05). P-values calculated using a 1-sided binomial distribution.  No other ectopic fat traits had a significant number of 154 
concordant associations for BMI SNPs and no ectopic fat traits had a significant number of concordant associations for WHR SNPs. 155 
 156 
BMI SNPS All Associations (N=97) Associations with P<0.05 
Trait 
# Direction 
Consistent 
1-sided 
Binomial P Total 
# Direction 
Consistent 
1-sided 
Binomial P 
SAT 87 8.9E-17 27 27 7.5E-09 
VAT 51 0.34 - - - 
VATadjBMI 43 0.89 - - - 
SATHU 55 0.11 - - - 
VATHU 49 0.50 - - - 
VAT/SAT ratio 42 0.92 - - - 
VAT/SAT ratio 
adjBMI 41 0.95 - - - 
WHR SNPs All Associations (N=49) Associations with P<0.05 
Trait 
# Direction 
Consistent 
1-sided 
Binomial P Total 
# Direction 
Consistent 
1-sided 
Binomial P 
SAT 22 0.80 - - - 
VAT 28 0.20 - - - 
VATadjBMI 29 0.13 - - - 
SATHU 21 0.87 - - - 
VATHU 24 0.61 - - - 
VAT/SAT ratio 27 0.28 - - - 
VAT/SAT ratio 
adjBMI 28 0.20 
- - - 
157 
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Supplementary Table 12.  Association between newly discovered SNPs and previously published GWAS of cardio-metabolic risk 158 
factors. 159 
      MAGIC (Meta-Analyses of Glucose and Insulin Consortium)10  
          
Fasting Glucose 
adjusted for BMI 
(N=58,074) 
Fasting Insulin 
adjusted for BMI 
(N=51,750) 
Trait Locus rsID A1/A2 A1_AF BETA SE P BETA SE P 
PATadjHtWt ENSA rs6587515 A/G 0.13 0.003 0.005 0.58 -0.011 0.005 0.01 
VATadjBMI GRAMD3 rs10060123 A/C 0.24 -0.001 0.004 0.90 -0.005 0.003 0.11 
PATadjHtWt EBF1 rs1650505 A/G 0.27 0.003 0.004 0.53 0.007 0.003 0.03 
VATadjBMI RREB1 rs2842895 C/G 0.59 -0.007 0.003 0.03 0.000 0.003 0.90 
SAT GDSMB rs2123685 T/C 0.95 0.001 0.008 0.93 0.011 0.007 0.11 
SATHU ATXN1 rs2237199 A/G 0.12 -0.001 0.005 0.81 -0.004 0.004 0.44 
VATSAT UBE2E2 rs7374732 T/C 0.63 0.001 0.003 0.85 0.005 0.003 0.11 
 160 
      
DIAGRAM (DIAbetes Genetics 
Replication And Meta-analysis)11 
      
Type 2 Diabetes 
(Ncases=26,488 and Ncontrols=83,964) 
Trait Locus rsID A1/A2 OR 95%CI P 
PATadjHtWt ENSA rs6587515 A/G 1.00 0.96-1.04 0.97 
VATadjBMI GRAMD3 rs10060123 A/C 0.98 0.95-1.01 0.21 
PATadjHtWt EBF1 rs1650505 A/G 1.04 1.01-1.07 0.11 
VATadjBMI RREB1 rs2842895 C/G 0.98 0.94-1.01 0.15 
SAT GDSMB rs2123685 T/C 1.03 0.95-1.13 0.44 
SATHU ATXN1 rs2237199 A/G 0.99 0.96-1.02 0.50 
VATSAT UBE2E2 rs7374732 T/C 0.94 0.92-0.96 1.3E-6 
 161 
 162 
 163 
 164 
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      GLGC (Global Lipids Genetics Consortium)12 
        
Triglycerides 
(N=91,013) 
High Density 
Lipoprotein 
Cholesterol  
(N=94,311) 
Total Cholesterol 
(N=94,595) 
Trait Locus rsID A1/A2 A1_AF BETA SE P BETA SE P BETA SE P 
PATadjHtWt ENSA rs6587515 G/A 0.92 0.003 0.008 0.89 0.007 0.008 0.55 0.008 0.009 0.45 
VATadjBMI GRAMD3 rs10060123 A/C 0.26 0.007 0.006 0.43 -0.004 0.006 0.82 -0.014 0.006 0.07 
PATadjHtWt EBF1 rs1650505 A/G 0.20 0.019 0.006 6.7E-4 -0.022 0.006 2.1E-4 0.008 0.006 0.22 
VATadjBMI RREB1 rs2842895 G/C 0.46 0.000 0.005 0.84 0.004 0.005 0.42 -0.001 0.005 0.76 
SAT GSDMB rs2123685 T/C 0.96 0.011 0.012 0.50 -0.014 0.012 0.11 0.007 0.013 0.80 
SATHU ATXN1 rs2237199 A/G 0.12 0.003 0.008 0.96 -0.007 0.008 0.97 -0.004 0.008 0.63 
VATSAT UBE2E2 rs7374732 T/C 0.65 0.005 0.005 0.19 0.005 0.005 0.32 0.003 0.005 0.44 
  165 
      Coronary Artery Disease 
      
CARDIoGRAM29 
(Ncases=21,846, Ncontrols=62,200) 
C4D30 
(Ncases=15,396, Ncontrols=15,046) 
Trait Locus rsID A1/A2 A1_AF OR 95%CI P A1/A2 A1_AF OR 95%CI P 
PATadjHtWt ENSA rs6587515 A/G 0.10 1.00 0.94-1.04 0.89 
VATadjBMI GRAMD3 rs10060123 A/C 0.28 1.01 0.97-1.04 0.55 
PATadjHtWt EBF1 rs1650505 A/G 0.22 1.01 0.97-1.04 0.45 G/A 0.28 0.99 0.95-1.02 0.62 
VATadjBMI RREB1 rs2842895 G/C 0.41 0.99 0.96-1.01 0.50 
SAT GSDMB rs2123685 T/C 0.92 1.01 0.94-1.07 0.80 
SATHU ATXN1 rs2237199 A/G 0.12 1.02 0.97-1.06 0.43 G/A 0.18 0.99 0.94-1.03 0.54 
VATSAT UBE2E2 rs7374732 T/C 0.63 1.00 0.97-1.02 0.99 C/T 0.33 1.02 0.98-1.05 0.28 
 166 
 167 
 168 
 169 
 170 
 171 
 172 
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 173 
      ICBP (International Consortium for Blood Pressure)13 
          
Systolic Blood 
Pressure  
(N=69,788) 
Diastolic Blood 
Pressure  
(N=69,783) 
Trait Locus rsID A1/A2 A1_AF BETA SE P BETA SE P 
PATadjHtWt ENSA rs6587515 G/A 0.92 0.032 0.166 0.85 0.098 0.106 0.35 
VATadjBMI GRAMD3 rs10060123 C/A 0.74 0.044 0.116 0.70 0.068 0.074 0.35 
PATadjHtWt EBF1 rs1650505 G/A 0.80 0.167 0.122 0.17 0.086 0.076 0.26 
VATadjBMI RREB1 rs2842895 G/C 0.46 0.053 0.101 0.60 0.003 0.064 0.96 
SAT GSDMB rs2123685 T/C 0.96 0.583 0.253 0.02 0.235 0.160 0.14 
SATHU ATXN1 rs2237199 G/A 0.88 0.160 0.164 0.33 0.059 0.103 0.57 
VATSAT UBE2E2 rs7374732 T/C 0.65 0.017 0.101 0.86 0.030 0.064 0.64 
Abbreviations  174 
N - Sample Size 175 
A1/A2 - Coded Allele/Non-Coded Allele 176 
 A1_AF - 1000 Genomes Project Allele Frequency 177 
 SE - Standard Error 178 
 P - P-value 179 
 OR - Odds Ratio 180 
 95%CI - 95% Confidence Interval 181 
PATadjHtWt - Pericardial Adipose Tissue adjusted for Height and Weight 182 
VATadjBMI - Visceral Adipose Tissue adjusted for Body Mass Index 183 
SAT - Subcutaneous Adipose Tissue 184 
SATHU - Subcutaneous Adipose Tissue Attenuation 185 
VATSAT - Visceral to Subcutaneous Adipose Tissue Ratio186 
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Supplementary Table 13.  SNP specific background information for newly discovered loci 187 
 188 
 
SNP name 
 
SNP location 
GWAS 
Catalog HaploReg14 Regulome DB15 
traits 
associated 
with SNP Promoter Enhancer DHS Score In adipose tissue? 
rs6587515 6.8kb 5' of ENSA NA NA ESC, ESDR, IPSC, BLD BLD 5 NA 
rs12045807 ENSA NA BLD  
ESDR, ESC, LNG, 
FAT, STRM, BRST, 
BLD, MUS, BRN, 
SKIN, LIV, GI, ADRL, 
PLCNT, THYM, HRT, 
PANC, SPLN, CRVX, 
VAS, BONE 
BLD, PLCNT 5 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
and adipose nuclei 
rs138805506 ENSA NA 
LNG, FAT, 
STRM, BLD, 
MUS, SKIN, 
BRN, GI, HRT, 
CRVX, LIV, 
BRST, VAS, 
BONE 
ESDR, BRST, BLD, 
SKIN, FAT, VAS, LIV, 
BRN, GI, ADRL, 
PANC, MUS, PLCNT, 
HRT, SPLN 
ESDR,LNG,BRST,
BLD 
SKIN,HRT,KID,LN
G,MUS,THYM,GI,O
VRY,PANC,CRVX,
LIV,VAS, BRN, 
4 
Possible enhancer in 
adipose nuclei and 
flanking active 
transcription start site in 
adipose derived 
mesnchymal stem cells 
and 
rs10060123 12kb 5' of GRAMD3 NA NA NA NA 7 NA 
rs6877526 7.8kb 5' of GRAMD3 NA NA 
ESDR, LNG, FAT, 
STRM, BRST, MUS, 
SKIN, GI, CRVX, 
VAS, BLD 
NA 5 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
rs1549189 7.5kb 5' of GRAMD3 NA NA 
ESDR, LNG, FAT, 
STRM, BRST, MUS, 
SKIN, ADRL, GI, 
CRVX, VAS 
NA 6 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
rs6595695 6.7kb 5' of GRAMD3 NA NA 
LNG, FAT, STRM, 
BRST, MUS, SKIN, 
BRN, ADRL, PLCNT, 
MUS 5 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
 34
 
SNP name 
 
SNP location 
GWAS 
Catalog HaploReg14 Regulome DB15 
traits 
associated 
with SNP Promoter Enhancer DHS Score In adipose tissue? 
GI, CRVX, VAS, 
BONE 
rs2080 6.4kb 5' of GRAMD3 NA NA 
ESDR, LNG, FAT, 
STRM, BRST, BLD, 
MUS, SKIN, GI, 
CRVX, VAS, BRN, 
BONE 
NA 5 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
rs1650505 93kb 3' of EBF1 
Age related 
hearing 
impairment 
NA NA NA 7 NA 
rs890945 31kb 3' of RP11-32D16.1 NA NA BLD, FAT NA 4 
Possible enhancer in 
adipose nuclei 
rs2963474 37kb 3' of RP11-32D16.1 NA NA FAT NA 7 NA 
rs2914224 37kb 3' of RP11-32D16.1 NA NA FAT NA 7 NA 
rs2963471 39kb 3' of RP11-32D16.1 NA NA FAT NA 6 
Possible enhancer in 
adipose nuclei 
rs1428443 39kb 3' of RP11-32D16.1 NA NA FAT NA 5 
Possible enhancer in 
adipose nuclei 
rs1428442 39kb 3' of RP11-32D16.1 NA NA FAT NA 5 
Possible enhancer in 
adipose nuclei 
rs2963470 40kb 3' of RP11-32D16.1 NA NA FAT NA 7 NA 
rs748510 65kb 3' of RP11-32D16.1 NA NA 
ESDR,FAT,BLD,SKI
N,BRN,LNG,THYM NA 7 NA 
rs890939 65kb 3' of RP11-32D16.1 NA NA 
ESDR, FAT, 
BLD,SKIN, BRN, 
MUS, THYM,LNG 
NA 7 NA 
rs890940 65kb 3' of RP11-32D16.1 NA NA 
ESDR, FAT, 
BLD,SKIN, BRN, 
MUS, THYM,LNG 
NA 7 NA 
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SNP name 
 
SNP location 
GWAS 
Catalog HaploReg14 Regulome DB15 
traits 
associated 
with SNP Promoter Enhancer DHS Score In adipose tissue? 
rs2842895 1.5kb 5' of RREB1 NA BLD 
ESDR,ESC,IPSC,BL
D,THYM,LIV LNG,BLD 4 NA 
rs11759956 RREB1 NA 
ESC, ESDR, 
LNG, IPSC, 
FAT, STRM, 
BRST, BLD, 
MUS, BRN, 
SKIN, VAS, LIV, 
GI, ADRL, KID, 
PANC, PLCNT, 
THYM, HRT, 
OVRY, SPLN, 
CRVX, BONE 
BRN BLD,KID,GI,THYM,MUS, LIV 2b 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
and adipose nuclei 
rs7451690 RREB1 NA 
ESC, ESDR, 
LNG, IPSC, 
FAT, STRM, 
BRST, BLD, 
MUS, BRN, 
SKIN, VAS, LIV, 
GI, ADRL, KID, 
PANC, PLCNT, 
THYM, HRT, 
OVRY, SPLN, 
CRVX, BONE 
BLD, BRN 
ESDR, BLD, SKIN, 
HRT, KID,MUS, GI, 
THYM, OVRY 
2b 
Active transcription site in 
adipose nuclei and 
adipose derived 
mesnchymal stem cells 
rs148697759 RREB1 NA 
ESC, ESDR, 
IPSC, STRM, 
BLD, MUS, 
SKIN, GI, HRT, 
PANC, LNG, 
ESC, ESDR, LNG, 
IPSC, FAT, BRST, 
BLD, BRN, SKIN, 
LIV, GI, KID, MUS, 
PLCNT, THYM, HRT, 
ESDR, BRST, BLD, 
SKIN, LNG, 
PLCNT, GI, LIV, 
BRST 
4 
Possible enhancer in 
adipose nuclei and 
adipose derived 
mesnchymal stem cells 
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SNP name 
 
SNP location 
GWAS 
Catalog HaploReg14 Regulome DB15 
traits 
associated 
with SNP Promoter Enhancer DHS Score In adipose tissue? 
LIV, BRST OVRY, BONE 
rs4960289 RREB1 NA 
ESC, IPSC, 
BRST, BLD, 
SKIN, GI, KID, 
THYM, PANC, 
MUS, LNG 
ESC, ESDR, LNG, 
IPSC, FAT, STRM, 
BLD, MUS, BRN, 
SKIN, VAS, LIV, GI, 
ADRL, HRT, PLCNT, 
SPLN, BONE 
ESC,BRST,SKIN,H
RT,GI,KID,LNG,PL
CNT, 
THYM,PANC,MUS,
LIV,BLD 
3a 
Possible enhancer in 
adipose nuclei and 
adipose derived 
mesnchymal stem cells 
rs2123685 7kb 3' of GSDMB NA NA NA NA 7 NA 
rs112599791 GSDMB NA GI FAT, LIV, GI, BLD GI,LIV 6  
rs113894104 GSDMB NA GI FAT, LIV, GI, BLD BLD,GI, LIV 2b possible enhancer in adipose nuclei 
rs3859186 GSDMB NA NA 
BLD, SKIN, FAT, LIV, 
GI, PLCNT, THYM, 
SPLN 
NA 2b 
Strong transcription in 
adipose derived 
mesnchymal stem cells 
and genic enhancer in 
adipose nuclei 
rs112260932 GSDMB NA BLD 
BLD, FAT, LIV, GI, 
MUS, PLCNT, 
THYM, SPLN 
BLD, ADRL,GI, 
THYM,OVRY,LIV 6 
Possible enhancer in 
adipose nuclei 
rs3169572 ORMDL3 NA BLD 
BLD, SKIN, FAT, LIV, 
GI, ADRL, MUS, 
PLCNT, THYM, 
SPLN 
BLD 4 
Strong transcription in 
adipose derived 
mesnchymal stem cells 
and genic enhancer in 
adipose nuclei 
rs3169574 ORMDL3 NA BLD 
BLD, SKIN, FAT, LIV, 
GI, ADRL, MUS, 
PLCNT, THYM, 
SPLN 
BLD 2b 
Strong transcription in 
adipose derived 
mesnchymal stem cells 
and genic enhancer in 
adipose nuclei 
rs78199107 ORMDL3 NA BLD 
BLD, SKIN, FAT, LIV, 
GI, ADRL, MUS, 
PLCNT, THYM, 
SPLN 
BLD, PLCNT, LIV 2b 
Strong transcription in 
adipose derived 
mesnchymal stem cells 
and genic enhancer in 
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SNP name 
 
SNP location 
GWAS 
Catalog HaploReg14 Regulome DB15 
traits 
associated 
with SNP Promoter Enhancer DHS Score In adipose tissue? 
adipose nuclei 
rs2237199 intronic ATXN1 NA NA BRN, GI NA 7 NA 
rs6809615  NA NA FAT, MUS, SKIN, BLD, VAS, LNG NA 6 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
rs7374732 29kb 5' of UBE2E2 NA BLD 
FAT, BLD, SKIN, 
LNG, BRN ESDR, BLD, SKIN 2b 
Possible enhancer in 
adipose derived 
mesnchymal stem cells 
*Abbreviations:  189 
DHS DNAse Hypersensitivity Site 190 
BLD Blood 191 
BRN Brain 192 
ESC Embryonic Stem Cells 193 
ESDR Embryonic Stem Derived Cultured Cells 194 
FAT Adipose Tissue 195 
GI Digestive Tract 196 
IPSC Induced Pluripotent Stem Cells 197 
LIV Liver 198 
LNG Lung 199 
SKIN Epithelial 200 
THYM Thymus201 
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Supplementary Table 14.  Gene-specific background information on newly identified loci. 202 
Gene Name Gene information 
ENSA A total of 32 genes are found within 500 kb of the lead marker, rs6587515. ENSα (endosulfine 
alpha, 1q21) is located 7 kb upstream from our lead marker. ENSα encodes protein that 
belongs to a highly conserved cAMP-regulated phosphoprotein (ARPP) family. This protein 
was identified as an endogenous ligand for the sulfonylurea receptor, ABCC8/SUR1. ABCC8 
is the regulatory subunit of the ATP-sensitive potassium (KATP) channel, which is located on 
the plasma membrane of pancreatic beta cells and plays a key role in the control of insulin 
release from pancreatic beta cells. SUR system seems also to be involved in human adipose 
tissue. The expression of SUR2B gene was higher in subcutaneous compared with omental 
adipose tissue and was not affected by weight loss (Gabrielsson et al. 2004).16 There are also 
two genes involved in development of obesity, CTSS and CTSK (Naour et al. 2010, Xiao et al. 
2006).17,18 CTSS (cathepsin K) is located at 94 kb downstream of our leader marker. CTSS 
plays a central role in extracellular matrix remodeling by stimulating adipocyte differentiation 
through degrading fibronectin. CTSK (cathepsin K) is located at 160 kb downstream of our 
leader marker. It encodes a lysosomal cysteine proteinase involved in extracellular matrix 
remodeling and could be one of the determinants of adipocyte differentiation. CTSK may be 
involved in the pathogenesis of obesity by promoting adipocyte differentiation (Xiao et al. 
2006).18 In addition, there are several biologically relevant genes within 1000 kb of the lead 
marker for regulatory role in Golgi complex (GOLPH3L), apoptosis (MCL1), cell cycle 
regulation (HORMAD1), transcriptional regulation (MIR4257, ECM1, ARNT, SETBD1, 
MRPS21, CIART, and GABPB2), threonine-tRNA ligase activity (TARS2), among others. 
GWA studies have reported associations within the 1Mb region of rs6587515 for fat body 
mass adjusted by lean body mass (rs2230061: p=4E-8, Pei et al. 2014),19 BMI (rs4357530: 
p=7.03E-14, Winkler et al. 2015),20 height (rs956796: p=1.7E-10, Wood et al. 2014),21 LDL 
cholesterol (rs267733: p=5E-9, Willer et al. 2013),12 prostate cancer (rs17599629: p=6E-23, Al 
Olama et al. 2014),22 melanoma (rs7412746: p=6E-23, Macgregor et al. 2014),23 
rhegmatogenous retinal detachment (rs267738: p=1E-7, Kirin et al. 2013),24 and chronic 
kidney disease (rs267734: p=1E-12, Köttgen et al. 2010).25 All of these markers appear to be 
independent of our lead SNP (r2<0.15). 
GRAMD3 A total of five genes are found within 500 kb of the lead marker, rs10060123. GRAMD3 
(GRAM domain containing 3, 5q23.2) is located 11.9 kb upstream from rs10060123. At 193.6 
kb downstream of this lead marker is located ALDH7A1 (5q31) gene, which encodes a 
member of subfamily 7 in the aldehyde dehydrogenase gene family. This enzyme degrades 
and detoxifies acetaldehyde generated by alcohol metabolism (cf. Guo et al. 2011).26 A 
significant GWA has been reported between osteoporosis with ALDH7A1-rs13182402 (p=2E-
09, Guo et al. 2011)26 that is in low LD with rs10060123 (r2=0.006). In addition, suggestive 
evidence of GWA has been found between GRAMD3 region with diabetic retinopathy 
(rs1073203: p=9E-06, Grassi et al. 2011),27 QT interval (rs1546498: p=5E-06, Smith et al. 
2012),28 cognitive outcomes in Parkinson's disease (rs959573: p=2E-06, Chung et al. 2012),29 
and cognitive tests (rs13169113: p=9E-06, Cirulli et al. 2010).30  
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Gene Name Gene information 
EBF1 The EBF1 (early B-cell factor 1, 5q34) is located 93 kb downstream from rs1650505. The 
EBF1 is the only gene located within 500 kb of this lead marker. EBF1 is a transcriptional 
activator, expressed in early B lymphocytes, adipocytes, and olfactory neurons (Hagman et al. 
2012, Milatovich et al. 1994).31,32  EBF1 negatively regulates estrogen receptors (ER) at the 
protein level (Le et al. 2013).33 It seems that EBF1 suppresses the expression and activity of 
ER, which consequently facilitates adipogenesis by up regulating adipogenic genes as well as 
by releasing PPARγ from the inhibition exerted by estrogen signaling (cf. Le et al. 2013).33 
Recently, a significant EBF1-psychosocial stress interaction GWA for hip circumference was 
reported (rs17056278: p=3E-8, Singh et al. 2015),34 but the SNP is in low LD with the leader 
markers (rs17056278 with rs1650505 or with rs2434264: r2<0.1). Additional GWA studies 
have shown association with blood pressure (rs11953630: p=3E-11 for systolic, and 
rs11953630: p=4E-13 for diastolic Ehret et al. 2011,13 and rs9313772: p=1E-11 for mean 
arterial pressure, Wain et al. 2011),35 longevity (90 years and older, rs2149954: p=2E-8, 
Deelen et al. 2014),36 breast cancer (rs1432679: p=2E-14, Michailidou et al. 2013),37 
neutropenia/ leucopenia response to anthracycline-based drugs (rs10040979: p=5E-7, Low et 
al. 2013),38 hypospadias (rs4563609: p=3E-7, Geller et al. 2014),39 eotaxin (rs13170526: 
p=4E-06, Comuzzie et al. 2012),38 and metabolite levels (dihydroxy docosatrienoic acid, 
rs11957368: p=4E-6, Yu et al. 2013).40 
RREB1 A total of eight genes are found within 500 kb of the lead marker, rs2842895. RREB1 (6p25), 
located 1.5 kb upstream from rs2842895, encodes a zinc finger transcription factor that binds 
to RAS-responsive elements (RREs) of gene promoters, including the calcitonin gene 
promoter. Another biological relevant gene located at 175 kb downstream from rs2842895 is 
the SSR1 (signal sequence receptor, alpha, 6p24.3). SSR1 encodes a glycosylated 
endoplasmic reticulum membrane receptor associated with protein translocation across the 
ER membrane. The association between rs2842895 with visceral adipose tissue adjusted for 
BMI was previously reported but did not reach a genomewide significance level (p=4E-6, Fox 
et al. 2012).41 There is also evidence of GWA between waist-hip ratio with rs1294421 (p=2E-
10, Berndt et al. 2013, p=2E-17, Heid et al. 2010)42,43 and with rs1294410 (p=2E-18, Locke et 
al. 2015),9 which are not in LD with the lead marker rs2842895 (r2=0.0). Several other loci 
from GWA studies have been reported on 6p24-6p25 region associated with body mass index 
(p=3E-8, Liu et al. 2013),44 type 2 diabetes (rs9502570: p=1E-9, Mahajan et al. 2014),11 BMI-
adjusted-fasting glucose (rs17762454: p=9.6E-9, Scott et al. 2012),45 fasting glucose-related 
traits interaction with BMI (rs11755724: p=3E-7, Manning et al. 2012),10 height (p=4.6E-14, 
Wood et al. 2014),21  interstitial lung disease (rs2076295: p=1E-19, Fingerlin et al. 2013),46 
urate levels (rs675209: p=1E-23, Köttgen et al. 2013, rs675209: p=1E-9, Yang et al. 
2010),47,48 multiple sclerosis (rs11755724: p=3E-6, Sawcer et al. 2011),49 age-related macular 
degeneration (rs11755724: p=1E-6, Neale et al. 2010),50 mammographic density non-dense 
area (rs1294438: p=1E-6, Lindström et al. 2014),51 and major depressive disorder 
(rs2326810: p=7E-6, Shyn et al. 2011).52 
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Gene Name Gene information 
GSDMB A total of 31 genes are found within 500 kb of the lead marker, rs2123685. GSDMB 
(gasdermin B, 17q12) is located 7 kb downstream from rs2123685. GSDMB and other genes 
on 17q12-q21 have shown association with inflammatory diseases, cancers, hematological 
parameters and/or metabolic traits. Five of the more biologically relevant genes that lie within 
the association signal region are ERBB2, NR1D1, THRα, RARα, and MED1. ERBB2 (erb-b2 
receptor tyrosine kinase 2, 17q12) is located 169 kb downstream from rs2123685. ERBB2 
encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine 
kinases. Experimental studies have indicated that up-regulation of signaling via ERBB2 and 
EGFR by leptin contributes to vascular dysfunction as seen in obesity, metabolic syndrome, 
and diabetes (cf., Bełtowski et al. 2014).53 NR1D1 (nuclear receptor subfamily 1, group D, 
member 1) is located 195 kb downstream from rs2123685. The encoded protein is a ligand-
sensitive transcription factor that regulates circadian rhythm and metabolism, influences 
adipocyte differentiation, and may also be involved in regulating genes that function in 
metabolic, inflammatory and cardiovascular processes (Wang et al. 2008, Fontaine et al. 
2003).54,55 THRα (thyroid hormone receptor, alpha, 17q11.2), located at 165 kb upstream from 
rs2123685, encodes a nuclear hormone receptor for triiodothyronine. It is one of the several 
receptors for thyroid hormone, and has been shown to mediate the biological activities of 
thyroid hormone. THRα is associated with obesity development (Fernández-Real et al. 
2013),56 and may contribute to subcutaneous adipose tissue expandability in obese subjects 
(Ortega et al. 2009).57 There is also a suggestion that differential interaction of NCoR1 
(nuclear receptor corepressor) with thyroid hormone receptor (TR) isoforms accounted for the 
TR isoform-dependent regulation of adipogenesis, and that aberrant interaction of NCoR1 
with TR could underlie the pathogenesis of lipid disorders in hypothyroidism (Zhu et al. 
2011).58 RARα (retinoic acid receptor, alpha) is located 412 kb upstream from rs2123685. The 
encoded protein, retinoic acid receptor alpha, regulates transcription in a ligand-dependent 
manner. RARα plays a role in regulation of development, differentiation, apoptosis, 
granulopoeisis, and transcription of clock genes.  Obesity was suggested to be associated 
with an inverse relationship between PPARγ (peroxisome proliferator-activated receptor 
gamma) and RARα expressions in human subcutaneous adipose tissue (Redonnet et al. 
2002).59 MED1 (mediator complex subunit 1) is located 446 kb from rs2123685. The activation 
of gene transcription is a multistep process that is triggered by factors that recognize 
transcriptional enhancer sites in DNA (cf. Chen et al. 2009).60 The protein encoded by this 
gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along 
with TFIID, is required for efficient activation by SP1. This protein is also a component of other 
multisubunit complexes, e.g. TR- associated proteins which interact with TR and facilitate TR 
function on DNA templates in conjunction with initiation factors and cofactors. In addition, 
MED1/TRAP220 is the nuclear receptor-interacting subunit of the MED and is required for 
PPARγ -stimulated adipogenesis (Ge et al. 2002).61 Several GWA studies have reported 
associations within the 1Mb region of rs2123685 for asthma (e.g., rs8069176: p=6E-23, 
Bønnelykke et al. 2014, rs11078927: p=2E-16, Torgerson et al. 2011),62,63 fractional exhaled 
nitric oxide in childhood (rs8069176: p=2E-8, van der Valk et al. 2014),64 self-reported allergy 
(rs9303280: p=9E-9, Hinds et al. 2013),65 Crohn's disease (rs2872507: p=2E-09, Franke et al. 
2010, rs2872507: p=5E-09, Barrett et al. 2008),66,67 type 1 diabetes (rs2290400: p=6E-13, 
Barrett et al. 2009),68 ulcerative colitis (rs2872507: p=5E-11, Anderson et al. 2011, 
rs2305480: p=3E-8, McGovern et al. 2010),69,70 rheumatoid arthritis (rs1877030: p=2E-8, 
Okada et al. 2014),71 primary biliary cirrhosis (rs9303277: p=4E-9, Nakamura et al. 2012, 
rs9303277: p=2E-9, Liu et al. 2010),72,73 inflammatory bowel disease (rs12946510: p=4E-38, 
Jostins et al. 2012),74 cervical cancer (rs2872507: p=9E-10, Shi et al. 2013),75 white blood cell 
count (e.g., rs4065321: p=1E-12, Crosslin et al. 2012, rs4065321: p=9E-35, Nalls et al. 2011, 
rs4065321: p=3E-14, Kamatani et al. 2010, rs17609240: p=9E-9, Soranzo et al. 2009),76-79 
and HDL cholesterol (e.g., rs11869286: p=3E-17, Willer et al. 2013).12  
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Gene Name Gene information 
ATXN1 A total of 3 genes are found within 500 kb of the lead marker, rs2237199. This marker is 
located within an intron in ATXN1 (6p22). Expansion of a CAG repeat in the coding region of 
ATXN1 causes spinocerebellar ataxia type 1 (SCA1) which belongs to the autosomal 
dominant cerebellar ataxias. Longer expansions of CAG result in earlier onset and more 
severe clinical manifestations of the disease characterized by progressive degeneration of the 
cerebellum that may lead to optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, 
peripheral neuropathy and dementia. However, the function of the ataxins is not known. GWA 
studies have shown association between variants on 6p22 with blood metabolite levels (p=2E-
16, Shin et al. 2014),80 electrocardiographic measure (QT interval: p=3E-10, Arking et al. 
2014),81 and cholesterol levels (total: p=2E-17, and LDL: p=2E-17, Willer et al. 2013).12 
Additional suggestive evidences of GWA have been reported between ATXN1 with disordered 
gambling (p=5E-06, Lind et al. 2013),82 major depressive disorder (p=1E-06, GENDEP 
Investigators et al. 2009),83 and amyotrophic lateral sclerosis (p=4E-06, Landers et al. 
2009).84 
UBE2E3 The UBE2E2 (3p24.2) is located 41 kb upstream from rs7374732, and the only gene located 
within 500 kb of this lead marker. UBE2E2 encodes the ubiquitin-conjugating enzyme E2E2, 
which expression in human pancreas, liver, muscle and adipose tissue (Yamauchi et al. 
2010).85 GWA studies have reported association between UBE2E2 region with type 2 
diabetes (rs6780569: p=4E-07, Hara et al. 2014, rs7612463: p=7E-09, Mahajan et al. 2014, 
and rs7612463: p=2.3E-09, Yamauchi et al. 2014)11,85,86 but the markers are in low LD with 
rs7374732 (with rs6780569: r2=0.034, and with rs7612463: r2=0.005).  Additional suggestive 
evidence of GWA for UBE2E2 have also been reported with atypical psychosis (rs4619807: 
p=2E-06, Kanazawa et al. 2013 ),87 colorectal cancer (rs4591517: p=3E-06, Jiao et al. 
2014),88 chronic kidney disease (rs9310709: p=2E-06, Gudbjartsson et al. 2010).89 
 203 
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Supplementary Table 15.  Mean variance explained by each newly identified ectopic fat locus. 204 
Variance explained was approximated using the following formula R2=β2var(SNP)/var(ectopic fat trait), 205 
where β2 is the estimated effect of the SNP on the ectopic fat trait, and var(SNP)=2*MAFSNP*(1-206 
MAFSNP).  Because sample-size weighted fixed-effect meta-analysis does not estimate effect sizes, the 207 
beta-coefficient for the association between the SNP and ectopic fat trait and the variance of the 208 
ectopic fat trait were obtained from cohort level analysis per contributing study.     209 
 210 
Trait Locus rsID Variance Explained 
PATadjHtWt ENSA rs6587515 0.28% 
VATadjBMI GRAMD3 rs10060123 0.23% 
PATadjHtWt EBF1 rs1650505 0.53% 
VATadjBMI RREB1 rs2842895 0.15% 
SAT GDSMB rs2123685 0.62% 
SATHU ATXN1 rs2237199 0.57% 
VATSAT UBE2E2 rs7374732 4.42% 
 211 
212 
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Supplementary Table 16.  Results from eQTL analysis of newly identified ectopic fat SNPs. Index 213 
SNPs and SNPs in LD with the index SNP (r2>0.8) across all ancestries available in the 1000 Genomes 214 
Project pilot (SNAP90).  A general overview of the larger collection of more than 50 eQTL studies from 215 
which the adipose-related datasets (omental, visceral and subcutaneous adipose,91-95). 216 
 217 
LOCUS SNPID Tissue P-value Transcript
ENSA rs12045807 Subcutaneous adipose tissue 93  4.53E-05 MRPS21 
ENSA rs2134688 Omental adipos tissue 92 9.17E-15 CTSK 
ENSA rs7517 Subcutaneous adipose tissue 93  4.27E-05 MRPS21 
ENSA rs7521445 Omental adipose tissue 92  9.48E-34 LASS2 
ENSA rs7521445 Subcutaneous adipose tissue 92  4.78E-23 LASS2 
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Supplementary Table 17.  Primer sequences used in qPCR analysis of murine adipose tissue. 218 
 219 
Gene Forward Primer Sequence Reverse Primer Sequence 
Ube2e2 ACTGAGGCGCAGAGAGTTGA GCTGAACTTGTTCTCGATCAGG 
Atxn1 CTCCCAAGAAACGTGAGATCC CCATTCCTTGTAAACCATGCTCC 
Rreb1 GCACTCTGGCGAGAGGCCTTAC GCTGCAGCTGTAGTACTGTTG 
Ebf1 GCATCCAACGGAGTGGAAG GATTTCCGCAGGTTAGAAGGC 
 220 
 221 
 222 
223 
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Supplementary Figure 1a.  Regional association plot for the ENSA locus in up to 12,204 women and 224 
men.  P-values for association were obtained using a sample-size weighted fixed-effects meta-analysis 225 
implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from SNAP.90  Plot 226 
was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
235 
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Supplementary Figure 1b.  Regional association plot for the GRAMD3 locus in up to 9,594 women.  236 
P-values for association were obtained using a sample-size weighted fixed-effects meta-analysis 237 
implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from SNAP.90   Plot 238 
was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   239 
 240 
241 
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Supplementary Figure 1c. Regional association plot for the EBF1 locus in up to 12,204 women and 242 
men.  P-values for association were obtained using a sample-size weighted fixed-effects meta-analysis 243 
implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from SNAP.90   Plot 244 
was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   245 
 246 
 247 
248 
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Supplementary Figure 1d. Regional association plot for the RREB1 locus in up to 18,332 women and 249 
men.  P-values for association were obtained using a sample-size weighted fixed-effects meta-analysis 250 
implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from SNAP.90   Plot 251 
was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   252 
 253 
254 
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Supplementary Figure 1e.  Regional association plot for the GSDMB locus in up to 9,562 women.  P-255 
values for association were obtained using a sample-size weighted fixed-effects meta-analysis 256 
implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from SNAP.90   Plot 257 
was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   258 
 259 
 260 
261 
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Supplementary Figure 1f. Regional association plot for the ATXN1 locus in up to 6,149 men.  P-262 
values for association were obtained using a sample-size weighted fixed-effects meta-analysis 263 
implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from SNAP.90   Plot 264 
was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   265 
 266 
267 
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Supplementary Figure 1g.  Regional association plot for the UBE2E2 locus in up to 18,191 women 268 
and men.  P-values for association were obtained using a sample-size weighted fixed-effects meta-269 
analysis implemented in METAL.6,7 Pairwise linkage disequilibrium estimates were obtained from 270 
SNAP.90  Plot was created using the gap R package (https://www.jstatsoft.org/article/view/v023i08).   271 
 272 
273 
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Supplementary Figure 2a.  Forest plots of Z-scores for rs6587515 (ENSA, pericardial fat locus) 274 
among combined sample of 11,027 women and men (NEuropean Ancestry=7,425; NAfrican Ancestry=1,442; NAsian 275 
Ancestry=761; NHispanic Ancestry=1,399).  276 
  277 
 278 
 279 
280 
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Supplementary Figure 2b.  Forest plots of Z-scores for rs10060123 (GRAMD3, visceral fat locus) 281 
among 9,623 women (NEuropean Ancestry=7,403; NAfrican Ancestry=2,220). 282 
  283 
284 
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Supplementary Figure 2c.  Forest plots of Z-scores for rs1650505 (EBF1, pericardial fat locus) among 285 
a combined sample of 11,566 women and men (NEuropean Ancestry=7,412; NAfrican Ancestry=1,994; NAsian 286 
Ancestry=761; NHispanic Ancestry=1,399). 287 
  288 
289 
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Supplementary Figure 2d.  Forest plots of Z-scores for rs2842895 (RREB1, visceral fat locus) among 290 
a combined sample of 17,297 women and men (NEuropean Ancestry=14,295; NAfrican Ancestry=3,002).  291 
Associations are calculated among the overall combined sample of women and men among family 292 
based studies unless otherwise indicated.  * indicates association among women in population-based 293 
study, + indicates association among men among population-based study. 294 
  295 
296 
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Supplementary Figure 2e.  Forest plots of Z-scores for rs2123685 (GSDMB, subcutaneous fat locus) 297 
among 7,137 women (NEuropean Ancestry=7,137). 298 
 299 
  300 
301 
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Supplementary Figure 2f.  Forest plots of Z-scores for rs2237199 (ATXN1, subcutaneous fat 302 
attenuation locus) among 5,780 men (NEuropean Ancestry=5,331; NAfrican Ancestry=499). 303 
  304 
 305 
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Supplementary Table 2g.  Forest plots of Z-scores for rs7374732 (UBE2E2, ratio of visceral-to-307 
subcutaneous fat locus) among a combined sample of 18,205 women and men (NEuropean Ancestry=14,674; 308 
NAfrican Ancestry=3,531).  Associations are calculated among the overall combined sample of women and 309 
men among family based studies unless otherwise indicated.  * indicates association among women in 310 
population-based study, + indicates association among men among population-based study. 311 
 312 
 313 
   314 
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Supplementary Figure 3a.  Linkage disequilibrium (LD) plots and genes within 500KB of rs6587515 315 
(index SNP at the ENSA locus). LD information obtained from HapMap2 CEU (top) and JPT+CHB 316 
(bottom). SNAP90 was used to create the LD plots and LD information was obtained from HapMap2. 317 
 318 
 319 
 320 
 321 
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Supplementary Figure 3b.  Linkage disequilibrium (LD) plots and genes within 500KB of rs10060123 323 
(index SNP at the GRAMD3 locus). LD information obtained from HapMap2 CEU (top) and YRI 324 
(bottom). SNAP90 was used to create the LD plots and LD information was obtained from HapMap2. 325 
 326 
 327 
 328 
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Supplementary Figure 3c.  Linkage disequilibrium (LD) plots and genes within 500KB of rs1650505  331 
(index SNP at the EBF1 locus). LD information obtained from HapMap2 CEU (top), YRI (middle), 332 
JPT+CHB (bottom). SNAP90 was used to create the LD plots and LD information was obtained from 333 
HapMap2. 334 
 335 
 336 
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Supplementary Figure 3d.  Linkage disequilibrium (LD) plots and genes within 500KB of rs2842895 339 
(the index SNP at the RREB1 locus). LD information obtained from HapMap2 CEU.  SNAP90 was used 340 
to create the LD plots and LD information was obtained from HapMap2. 341 
 342 
 343 
 344 
345 
 64
Supplementary Figure 3e.  Linkage disequilibrium (LD) plots and genes within 500KB of rs2123685 346 
(index SNP at the GSDMB locus). LD information obtained from HapMap2 CEU.  SNAP90 was used to 347 
create the LD plots and LD information was obtained from HapMap2. 348 
 349 
 350 
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Supplementary Figure 3f.  Linkage disequilibrium (LD) plots and genes within 500KB of rs2237199 352 
(the index SNP at the ATXN1 locus). LD information obtained from HapMap2 CEU (top) and YRI 353 
(bottom).  SNAP90 was used to create the LD plots and LD information was obtained from HapMap2. 354 
 355 
 356 
 357 
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Supplementary Figure 3g.  Linkage disequilibrium (LD) plots and genes within 500KB of rs7374732 359 
(the index SNP at the UBE2E2 locus). LD information obtained from HapMap2 CEU (top) and YRI 360 
(bottom).  SNAP90 was used to create the LD plots and LD information was obtained from HapMap2. 361 
 362 
 363 
 364 
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Supplementary Figure 4a. Manhattan plot and QQ plots for subcutaneous adipose tissue volume 366 
(SAT) analysis. P-values for association were obtained using a sample-size weighted fixed-effects 367 
meta-analysis implemented in METAL. 6,7 Order of analyses in panels is: a) OVERALL, N=18,247, b) 368 
WOMEN, N=9,562, c) MEN, N=8,685. 369 
   370 
 371 
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Supplementary Figure 4b. Manhattan plot and QQ plots for visceral adipose tissue volume (VAT). 373 
analysis. P-values for association were obtained using a sample-size weighted fixed-effects meta-374 
analysis implemented in METAL.6,7 Order of analyses in panels is: a) OVERALL, N=18,332, b) 375 
WOMEN, N=9,694, c) MEN, N=8,738.  376 
 377 
 378 
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Supplementary Figure 4c.  Manhattan plot and QQ plots for visceral adipose tissue volume adjusted 380 
for BMI (VATadjBMI) analysis. P-values for association were obtained using a sample-size weighted 381 
fixed-effects meta-analysis implemented in METAL.6,7 Order of analyses in panels is: a) OVERALL, 382 
N=18,287, b) WOMEN, N=9,862, c) MEN, N=8,435. 383 
 384 
 385 
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Supplementary Figure 4d.  Manhattan plot and QQ plots for pericardial adipose tissue volume  (PAT) 387 
analysis. P-values for association were obtained using a sample-size weighted fixed-effects meta-388 
analysis implemented in METAL.6,7 Order of analyses in panels is: a) OVERALL, N=12,204, b) 389 
WOMEN, N=6,362, c) MEN, N=5,842. 390 
 391 
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Supplementary Figure 4e.  Manhattan plot and QQ plots for pericardial adipose tissue volume 393 
adjusted for Height and Weight (PATadjHtWt) analysis. P-values for association were obtained using a 394 
sample-size weighted fixed-effects meta-analysis implemented in METAL.6,7 Order of analyses in 395 
panels is: a) OVERALL, N=11,583, b) WOMEN, N=6,110, c) MEN, N=5,473. 396 
 397 
 398 
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Supplementary Figure 4f.  Manhattan plot and QQ plots for subcutaneous adipose tissue attenuation 400 
(SATHU) analysis. P-values for association were obtained using a sample-size weighted fixed-effects 401 
meta-analysis implemented in METAL.6,7 Order of analyses in panels is: a) OVERALL, N=12,439, b) 402 
WOMEN, N=6,291, c) MEN, N=6,149. 403 
404 
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 405 
 406 
Supplementary Figure 4g.  Manhattan plot and QQ plots for visceral adipose tissue attenuation 407 
(VATHU) analysis. P-values for association were obtained using a sample-size weighted fixed-effects 408 
meta-analysis implemented in METAL.6,7 Order of analyses in panels is: a) OVERALL, N=12,519, b) 409 
WOMEN, N=6,321, c) MEN, N=6,199. 410 
 411 
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Supplementary Figure 4f.  Manhattan plot and QQ plots for ratio of visceral adipose tissue 413 
volume to subcutaneous adipose tissue volume (VAT/SAT ratio). P-values for association were 414 
obtained using a sample-size weighted fixed-effects meta-analysis implemented in METAL.6,7 415 
Order of analyses in panels is: a) OVERALL, N=18,191, b) WOMEN, N=9,823, c) MEN, N=8,374.  416 
417 
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Supplementary Figure 4g Manhattan plot and QQ plots for ratio of visceral adipose tissue volume to 418 
subcutaneous adipose tissue volume adjusted for BMI (VAT/SAT ratio adj BMI). P-values for 419 
association were obtained using a sample-size weighted fixed-effects meta-analysis implemented in 420 
METAL.6,7 Order of analyses in panels is: a) OVERALL, N=18,190, b) WOMEN, N=9,815, c) MEN, 421 
N=8,375.  422 
 423 
 424 
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Supplementary Figure 5. Functional characterization of Ebf1 and Rreb1.   426 
Gene expression measured by qPCR in culture adipocyte progenitors isolated from the subcutaneous 427 
(SAT) or perigonadal visceral (VAT) depots (n=4). Cells were expanded to confluence and then 428 
collected at intervals after induction of adipogenic differentiation. Data was expressed as mean, error 429 
bar=s.e.m.  Statistical significance was assessed using Kruskal-Wallis test and Dunn’s correction for 430 
multiple comparisons. 431 
  432 
 433 
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Supplementary Figure 6. Sex-specific expression of Atxn1 in murine adipose tissue.   435 
Because the ATXN1 association was confined to males, we considered the possibility that Atxn1 436 
expression in murine adipose tissue would be dependent on sex and measured its expression by qPCR 437 
in adipose depots of male and female mice (n=6). In the three analyzed depots, no sex-specific 438 
difference was observed. These data do not exclude a gender-specific expression pattern at other 439 
developmental time-points or in specific pathophysiologic contexts. Data is displayed as box/whisker 440 
plot where center line=median, box spans 25th-75th percentiles, whiskers span max/min values.  441 
 442 
443 
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Supplementary Note 444 
Cohort Specific Information and Protocols 445 
 446 
AGES - The Age, Gene/Environment Susceptibility Reykjavik Study 447 
AGES-Reykjavik Study. The Reykjavik Study cohort originally comprised a random sample of 30,795 448 
men and women born in 1907-1935 and living in Reykjavik in 1967. A total of 19,381 people attended, 449 
resulting in 71% recruitment rate. The study sample was divided into six groups by birth year and birth 450 
date within month. One group was designated for longitudinal follow up and was examined in all stages. 451 
One group was designated a control group and was not included in examinations until 1991. Other 452 
groups were invited to participate in specific stages of the study. Between 2002 and 2006, the AGES-453 
Reykjavik study96 re-examined 5764 survivors of the original cohort who had participated before in the 454 
Reykjavik Study. The AGES-Reykjavik Study GWAS was approved by the National Bioethics 455 
Committee (VSN: 00-063) and the Data Protection Authority. 456 
 457 
Abdominal adipose tissue measurements: 458 
Computed tomography (CT) imaging of the abdomen at the L4/L5 vertebrae was performed with a 4-459 
row detector system (Sensation; Siemens Medical Systems, Erlangen, Germany) as described 460 
previously.97 Visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT) were 461 
estimated from a single 10-mm thick trans-axial section. Images were loaded into an AVS5 display 462 
environment. Visceral adipose tissue was distinguished from subcutaneous adipose tissue by tracing 463 
along the facial plane defining the internal abdominal wall. Adipose areas were calculated by 464 
multiplying the number of pixels by the pixel area using specialized software (University of California, 465 
San Francisco).  466 
 467 
Amish 468 
We included in this study individuals in whom CT scans were obtained to measure the quantity of 469 
coronary artery calcification. The scans were obtained using electron beam computed tomography 470 
(EBCT) on men aged 30 years and older and women aged 40 years and older recruited for studies of 471 
cardiovascular health (the Amish Family Calcification Study, 2002-2005 and the Amish Longevity 472 
Study, 2000-2008) from the Lancaster County, Pennsylvania Amish community. The design of these 473 
two studies has been previously described98,99. Study subjects were relatively healthy. The Amish 474 
Family Calcification Study was initiated to identify the determinants of vascular calcification and to 475 
evaluate the relationship between calcification of bone and vascular tissue in the Old Order Amish 476 
community. Participants were recruited based on their participation in an earlier study of bone mineral 477 
density; later the recruitment was open to their first and second-degree relatives. The longevity study 478 
was based on Amish who lived past the age of 90 years, their offspring, and the spouses of these 479 
offspring.  All analyses were approved by the Institutional Review Board of University of Maryland, 480 
Baltimore. 481 
 482 
Pericardial Fat Assessment 483 
Non-contrast Electron Beam Computed Tomography (EBCT) scan was performed on an Imatron 484 
scanner (Imatron Inc. San Francisco, CA) in 3-mm thick contiguous slices with pixel size of 485 
0.7813*0.7813 mm. Participants with complete scan from the root of major heart arteries to the apex of 486 
the heart and covered the full length of heart were included in the study.  487 
 488 
Pericardial fat volume was defined as fat volume within the fibrous pericardium. We utilized the Medical 489 
Image Processing, Analysis, and Visualization (MIPAV) application for our volume measurements. 490 
Adipose tissue volumes (cm3) were measured without knowledge of the subject’s coronary calcification 491 
score. Manual segmentation of the adipose tissue inside and outside of the pericardial sac was done by 492 
drawing regions-of-interest (ROIs) on every selected slice. A threshold of -190 to -30 Hounsfield units 493 
was applied to identify adipose tissue voxels. Our fat volume measurement has both high inter-494 
observer and intra-observer reproducibility (0.92 and 0.96, respectively)  495 
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 496 
Imputation  497 
Genotyping was performed using either the Affymetrix GeneChip Human Mapping 500K Array or 6.0 498 
Array set (Affymetrix, Santa Clara, CA, USA) and included a total of 500,568 single nucleotide 499 
polymorphisms (SNPs). The Affymetrix GeneChip Genotyping Analysis Software and BRLMM 500 
genotype-calling algorithm (Affymetrix) were used to generate SNP data files. Mean sample call rate 501 
was 98.3% after filtered by relationship check and call rate (>95%). A total of 373, 825 SNPs that 502 
passed quality control (SNP call rate >95%, minor allele frequency (MAF) >0) and Hardy–Weinberg 503 
Equilibrium checks (at P>0.0001) were retained for analysis. 504 
 505 
As a reference panel for imputation, we used Phase II CEU HapMap individuals for imputation and 506 
MACH v1.0.15/16 (http://www.sph.umich.edu/csg/abecasis/MACH/). A total of 338,598 autosomal 507 
SNPs were used for imputation after applying the filters: (1) not in HapMap, (2) frequency <0.01, (3) 508 
Hardy-Weinberg p<1 x 10⎯6, and (4) missingness >0.05. 509 
 510 
Statistical analysis  511 
We performed genome-wide association of pericardial fat volume using a mixed model approach that 512 
models variation in pericardial fat volume as a function of SNP genotype, with adjustment for age, sex, 513 
and a polygenic component to account for the family relatedness among study subjects. We used the 514 
Mixed Model Analysis Program (MMAP) software program for analysis.  515 
 516 
DHS - Diabetes Heart Study 517 
All analyses were approved by the Institutional Review Board at Wake Forest University, School of 518 
Medicine.  519 
 520 
The Abdominal CT scan series was performed on multi-dectector CT scanners (CTi, LIghtSpeed QXI, 521 
Pro16 and VCT, GE Medical Systems, Waukesha WI) in a helical scan mode, 120 KVP, 160 mAs, 2.5 522 
mm slice collimation and standard reconstruction kernal. 523 
 524 
Abdominal adipose tissue measurements  525 
Abdominal fat volumes were measured from a 50 cm DFOV CT scan series with a 2.5 mm slice 526 
collimation to cover 60 mm (24 slices each 2.5 mm thick) of abdomen. Measurements were centered 527 
on the lumbar disk space centered at L4-L5. Subcutaneous and visceral adipose tissue volumes (SAT 528 
and VAT, respectively) were assessed with volume analysis software (Advantage Windows; GE 529 
Healthcare, Waukesha, WI). Fat volumes in the different compartments were measured by analysts 530 
using a semi-automatic segmentation technique. A tissue attenuation using a threshold of -190 to -30 531 
Hounsfield Units (HU) was used to characterize each voxel as adipose tissue. 532 
 533 
FamHS - Family Heart Study 534 
The Family Heart Study (FamHS) is a multicenter, population-based, family study designed to 535 
investigate the determinants of cardiovascular disease. The collection of phenotypes and covariates as 536 
well as clinical examination have been previously described for the FamHS100 537 
(https://dsgweb.wustl.edu/fhscc/).    538 
 539 
In brief, the FamHS recruited 1,200 families (approximately 6,000 individuals), half randomly sampled, 540 
and half selected because of an excess of CHD or risk factor abnormalities as compared with age- and 541 
sex-specific population rates. The participants were sampled from four population-based parent 542 
studies: the Framingham Heart Study, the Utah Family Tree Study, and two centers for the 543 
Atherosclerosis Risk in Communities study (ARIC: Minneapolis, and Forsyth County, NC). Between 544 
2002 and 2003 about two-thirds of the largest families were invited to participate in a follow-up clinical 545 
examination that included measurement of the liver and abdomen with cardiac CT using standardized 546 
procedures and quality control methods developed in NHLBI's MESA and CARDIA studies101. Informed 547 
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consent was obtained from all participants and this project was approved by the Institutional Review 548 
Boards of all participating institutions. A total of 2,659 European descent subjects with CT measures 549 
participated in the GWA current study.  550 
 551 
Family Heart Study CT exam:  552 
Research CT exams of the chest for CAC and abdomen for measurement of abdominal body 553 
compensation were obtained from 5 field centers with one field center using 2 CT scan sites. The 554 
following CT scanner systems were used: GE LightSpeed Plus, Siemens Volume Zoom, GE 555 
LightSpeed Ultra, Marconi MX8000 and GE LightSpeed Plus, GE LIghtSpeed QXi. For the abdominal 556 
scan the following technique was utilized: helical (aka Spiral) scan, 120KVp, 150 mAs, gantry speed 557 
0.8s, standard kernal, full reconstruction and pitch 3:1 ( 7.5 mm table travel over 2.5 mm slice). Images 558 
were reconstructed into both a 35 and 50 cm display field of view to include a calibration phantom 559 
(Image Analysis, Columbia, KY, USA) which was positioned under the abdomen of each subject. 560 
 561 
Volumetric adipose tissue imaging  562 
Participants underwent a cardiac MDCT exam with four detectors using a standardized protocol as 563 
described previously101. For participants weighing 100 kg (220 lbs) or greater, the mAs were increased 564 
by 25%. The effective radiation exposure for the average participant of each coronary scan was 1.5 565 
mSv for men and 1.9 mSv for women. Participants received two sequential scans. CT images from all 566 
study centers were sent electronically to the central CT reading center located at Wake Forest 567 
University Health Sciences, Winston Salem, NC, USA. 568 
 569 
Abdominal adipose tissue measurements  570 
CT scans of the abdomen were reconstructed into 5 mm slices with the maximum 50 cm field-of-view to 571 
include the whole abdomen for body composition.  Total and adipose tissues were measured 572 
volumetrically from two 5 mm contiguous slices located at the level of the lumbar disk between the 4th 573 
and 5th vertebra. Tissues with attenuation between -190 to -30 Hounsfield units were defined as 574 
adipose tissue. The Medical Image Processing, Analysis, and Visualization (MIPAV, 575 
[http://mipav.cit.nih.gov/index.php]) application was used by experienced analysts to segment the 576 
images based on anatomic boundaries (skin, subcutaneous fat-muscle interface and peritoneum) into 577 
the entire abdomen, abdominal wall and intra-abdominal compartments. In each compartment, we 578 
quantified total abdominal volume, total abdominal adipose tissue, subcutaneous adipose tissue and 579 
visceral adipose tissue contained within the 10 mm slice located at L4-5. Inter-observer variability 580 
based on the re-analysis of randomly selected 365 scans from the core study population by an expert 581 
observer showed an average correlation coefficient of 0.99. Intra-observer variability based on re-582 
analysis of 45 scans by each of the four observers resulted in an average correlation coefficient of 0.99.  583 
 584 
Pericardial Fat Assessment  585 
Pericardial adipose tissue (PAT) volume in heart (cm3) was also performed on the CT images after 586 
segmentation of the heart and surrounding adipose tissue from the remainder of the thorax using 587 
specific anatomic landmarks. The PAT volume was the sum of all pericardial fat voxels over the 4.5-cm 588 
volume (cubic centimeters/ 4.5 cm) 589 
 590 
Imputation  591 
As a reference panel for imputation, we used Phase II CEU HapMap individuals; we imputed genotypes 592 
to nearly 2.5 million HapMap SNPs; further details are presented in Supplementary Table 3.  593 
 594 
Statistical analysis  595 
We performed linear regression modeling for SAT, VAT, VAT/SAT, and PAT. 596 
 597 
 598 
 599 
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FELS 600 
The Fels Longitudinal Study began in 1929 and is the oldest continuous study of growth, development, 601 
and aging in the world102 (ISBN 052137449). From its beginning, participants in the Fels Longitudinal 602 
Study have not been selected based on health status or any other obesity-, CVD-, or T2DM-related 603 
trait. Enrollment in the study began with some 10 newborns per year, increasing since the 1930s to 15 - 604 
20 per year. The methodology and design have been described in Roche (ISBN 052137449). Each 605 
participant is followed from enrollment (usually birth) until death or infirmity rendering their continued 606 
participation impossible. Participants are not examined when menstruating, pregnant, or having other 607 
transient conditions (e.g., ill with infectious disease) that could affect specific data collected. All 608 
protocols were approved by the Institutional Review Board of the Boonshoft School of Medicine, Wright 609 
State University. 610 
 611 
Currently, there are 1259 mostly white, non Hispanic, active participants in the Fels Longitudinal Study 612 
(HD012252, SA Czerwinski, PI), with the oldest participants with long-term serial data from birth now in 613 
their 80s. Since 2002, MRI assessment of abdominal obesity has been performed on a subset of Fels 614 
Longitudinal Study participants, initially as part of other research (DK064391, B Towne, PI). Currently, 615 
635 active adult participants have had SAT and VAT data measured from a single MRI assessment of 616 
abdominal adiposity, and of these 578 have been SNP genotyped.  617 
 618 
Principal components were calculated using 27, 966 cleaned Illumina SNPs that had minimal linkage 619 
disequilibrium (r < 0.1) across a 2Mb sliding window, and that had a relatively high minor allele 620 
frequency (15.5%) for our entire sample of SNP genotyped participants. From these participants, 452 621 
unrelated participants were identified using the unrelate command in PEDSYS 622 
(http://www.txbiomed.org/departments/genetics/genetics-detail?r=42). Principal components analysis 623 
was performed on the 27,966 genotype scores of the 452 unrelated participants using prcomp in R 624 
(http://www.r-project.org). PC scores for all genotyped participants were calculated from the loadings 625 
using predict in R.  626 
 627 
Volumetric adipose tissue imaging  628 
Using a previously described protocols103,104, MR Images were obtained using a research-dedicated 629 
Siemens Magnetom Avanto 1.5 Tesla whole body scanner, at Kettering Medical Center, Dayton, OH. 630 
Contiguous axial images were acquired across the entire abdominal region (T9 – S1). Slice thickness 631 
was 1 cm, and images were obtained every 1 cm. Depending on the height of the participant, the 632 
number of images ranged from 21 to 40 slices.  633 
 634 
Abdominal adipose tissue measurements  635 
SliceOmatic software (Tomovision Inc., Montreal, Canada) image analyses was performed to segment 636 
tissues and quantify VAT and SAT. First, trained technicians performed gray scale standardization to 637 
determine the best brightness settings to differentiate between different gray-level regions on each 638 
image. The gray level threshold for various tissues (i.e. VAT, and SAT) was then set and used to 639 
identify each tissue type. Each image was then reviewed and where necessary, segmentation was 640 
corrected. The area (cm2) of VAT and SAT in each image was then computed by summing the VAT 641 
and SAT tissue pixels and multiplying by the individual pixel surface area. The VAT and SAT tissue 642 
areas were then summed across all images to obtain volumes for VAT and SAT.  643 
 644 
Imputation  645 
As a reference panel for imputation, we used Phase II CEU HapMap individuals; we imputed genotypes 646 
to nearly 2.5 million HapMap SNPs; further details are presented in Supplementary Table 1. We used 647 
MACH v1.0 (http://www.sph.umich.edu/csg/abecasis/MACH/), and accounted for participant 648 
relatedness. We expressed imputed genotypes as allelic dosage (which is a fractional value ranging 649 
from 0-2).  650 
 651 
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Statistical analysis  652 
We performed linear mixed effects regression modeling to account for pedigree structure using 653 
SOLAR.1 654 
 655 
FHS - Framingham Heart Study 656 
In 1948, the Framingham Heart Study began when the Original Cohort was enrolled.105 Beginning in 657 
1971, the Offspring Cohort was enrolled (5,124 participants); the methodology and design has been 658 
described. In 2002, the Third Generation cohort was enrolled (n = 4095).106 Participants for this study 659 
were drawn from the Framingham Heart Study Multi-detector Computed Tomography (MDCT) Study, a 660 
population-based sub-study of the community-based Framingham Heart Study Offspring and Third 661 
Generation cohorts. Participants for the current study were drawn from the MDCT sub-study. All 662 
protocols and analyses were approved by the Institutional Review Board at Boston University School of 663 
Public Health and National Heart, Lung and Blood Institute.  Between June 2002 to April 2005, 3529 664 
participants (2111 Third Generation, 1418 Offspring participants) underwent MDCT assessment of 665 
coronary and aortic calcium. Inclusion in this study was weighted towards participants from larger 666 
Framingham Heart Study families and those who resided in the Greater New England area. Men had to 667 
be at least 35 years of age, women had to be at least 40 years of age and non-pregnant, and all 668 
participants had to weigh less than 350 pounds. Of the total of 3529 subjects imaged, 3394 had 669 
interpretable CT measures, 3329 of whom had both SAT and VAT measured, and 3158 participated in 670 
the present GWAS study. 671 
 672 
We observed association with the first principle components estimated using EIGENSTRAT;107 this was 673 
accounted for in our analyses.  674 
 675 
Volumetric adipose tissue imaging  676 
Subjects underwent eight-slice MDCT imaging of the chest and abdomen in a supine position as 677 
previously described (LightSpeed Ultra, General Electric, Milwaukee, WI).108 Briefly, twenty-five 678 
contiguous five mm thick slices (120 kVp, 400 mA, gantry rotation time 500 ms, table feed 3:1) were 679 
acquired covering 125 mm above the level of S1.  680 
 681 
Abdominal adipose tissue measurements  682 
Subcutaneous and visceral adipose tissue volumes (SAT and VAT) were assessed (Aquarius 3D 683 
Workstation, TeraRecon Inc., San Mateo, CA). In order to identify pixels containing fat, an image 684 
display window width of -195 to -45 Hounsfield Units (HU) and a window center of -120 HU were used. 685 
The abdominal muscular wall separating the visceral from the subcutaneous compartment was 686 
manually traced. Average HU per fat depot was recorded. Inter-reader reproducibility was assessed by 687 
two independent readers measuring VAT and SAT on a subset of 100 randomly selected 688 
participants.108 Inter-class correlations for inter-reader comparisons were 0.992 for VAT and 0.997 for 689 
SAT. Similar high correlations were noted for intra-reader comparisons.  690 
 691 
Pericardial Fat Assessment  692 
Framingham Heart Study participants underwent MDCT utilizing 8-slice MDCT in a supine position 693 
(LightSpeed Ultra, General Electric, Milwaukee, WI). On average, 48 contiguous 2.5 mm slices of the 694 
heart were acquired with prospectively ECG triggered CT scanning protocol (120 kVp, 400 mA, 695 
temporal resolution 330 ms).  We measured pericardial fat tissue volumes (cm3) with a dedicated 696 
offline workstation (Aquarius 3D Workstation, TeraRecon Inc., San Mateo, CA) based on the principle 697 
that absolute Hounsfield Units (HU) values correspond to tissue property. Thus, we set a predefined 698 
image display (window width -195 to -45 HU; window center -120 HU) to identify pixels that correspond 699 
with adipose tissue. Pericardial fat was measured across the complete available imaging volume in 700 
cm3.  We used a semi-automatic segmentation technique which required the reader to manually trace 701 
the pericardium. We defined pericardial fat volume as adipose tissue located within the pericardial sac. 702 
Using a random sample of 100 participants, intra-reader (ICC 0.97) and inter-reader (ICC 0.95) 703 
 83
reproducibility was excellent.109  704 
 705 
Imputation  706 
As a reference panel for imputation, we used Phase II CEU HapMap individuals; we imputed genotypes 707 
to nearly 2.5 million HapMap SNPs; further details are presented in Supplementary Table 1. We used 708 
MACH v1.0.15/16 (http://www.sph.umich.edu/csg/abecasis/MACH/), and accounted for participant 709 
relatedness. We expressed imputed genotypes as allelic dosage (which is a fractional value ranging 710 
from 0-2).  711 
 712 
Statistical analysis  713 
We performed linear mixed effects regression modeling to account for pedigree structure (R kinship 714 
package). 715 
 716 
GENOA - Genetic Epidemiology Network of Arteriopathy 717 
GENOA is one of four networks in the NHLBI Family-Blood Pressure Program (FBPP).110,111  GENOA's 718 
long-term objective is to elucidate the genetics of target organ complications of hypertension, including 719 
both atherosclerotic and arteriolosclerotic complications involving the heart, brain, kidneys, and 720 
peripheral arteries. The longitudinal GENOA Study recruited European-American and African-American 721 
sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. 722 
All other members of the sibship were invited to participate regardless of their hypertension status. 723 
Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis of 724 
hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic blood 725 
pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg based on the second and third readings 726 
at the time of their clinic visit. Exclusion criteria were secondary hypertension, alcoholism or drug 727 
abuse, pregnancy, insulin-dependent diabetes mellitus, or active malignancy. During the first exam 728 
(1995-2000), 1,583 European Americans from Rochester, MN and 1,854 African Americans from 729 
Jackson, MS were examined.  730 
 731 
Between 2009 and 2011, 657 self-identified African American GENOA participants at the Jackson, 732 
Mississippi Field Center received computed tomography (CT) scans for coronary artery calcification, 733 
abdominal adipose tissue, and pericardial adipose tissue. Participants weighing more than 160 kg were 734 
excluded from the CT scan. The final sample included 552 GENOA participants with CT measures and 735 
GWAS data. Jackson Heart Study participants who also participated in GENOA were not included in 736 
the analyses as part of the Jackson Heart Study but were included as part of the GENOA Cohort. Study 737 
protocols were approved by the University of Mississippi and University of Michigan Institutional Review 738 
Boards and participants gave written informed consent.  739 
 740 
Volumetric adipose tissue imaging  741 
CT scans of the lower abdomen and heart were obtained with a GE LightSpeed Pro 16 multidetector 742 
scanner (GE Healthcare, Milwaukee, WI). The scans were reconstructed using display field-of-view 743 
(DFOV) of 35 cm and 50 cm and a Calcium QCT phantom was included in the images. For participants 744 
who weighed more than 100 kg, the tube current (i.e., mA) was adjusted upwards (25%). This 745 
adjustment was designed to maintain a more consistent image quality over the spectrum of body sizes. 746 
The estimated average whole-body effective dose for the entire protocol was 4 mSv. CT images were 747 
transmitted to the reading center at Wake Forest University.  748 
 749 
Briefly, abdominal fat volumes were measured from a 50 cm DFOV CT scan series with a 2.5 mm slice 750 
collimation to cover 60 mm (24 slices each 2.5 mm thick) of abdomen from L3 to S1. Scanning was 751 
centered on the lumbar disk space centered at L4-L5.112  Pericardial adipose tissue was measured from 752 
a 35 cm DFOV CT scan series of the heart with a 2.5 mm slice collimation starting 15 mm above and 753 
ending 30 mm below the superior extent of the left main coronary artery for coverage of 45 mm (18 754 
slices each 2.5 mm thick) along the head-foot (z-axis) of the participant.112 755 
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Abdominal adipose tissue measurements  756 
Subcutaneous and visceral adipose tissue volumes (SAT and VAT, respectively) were assessed with 757 
volume analysis software (Advantage Windows; GE Healthcare, Waukesha, WI). The abdominal 758 
muscular wall separating the visceral from the subcutaneous compartment was manually traced. Fat 759 
volumes in the different compartments were measured by a semiautomatic segmentation technique. A 760 
tissue attenuation using a threshold of -190 to -30 Hounsfield Units (HU) was used to characterize each 761 
voxel as fat.113  Using this protocol, inter-class correlations for inter-reader comparisons were previously 762 
shown to be 0.95 for VAT and SAT.113 763 
 764 
Pericardial Fat Assessment  765 
Pericardial fat volume (PAT) was assessed with volume analysis software (Advantage Windows; GE 766 
Healthcare, Waukesha, WI). PAT was measured after segmentation of the heart and surrounding 767 
adipose tissue from the remainder of the thorax using specific landmarks. PAT was measured as a 768 
combination of pericardial and epicardial fat because it is difficult to distinguish the two fat measures on 769 
CT images. A tissue attenuation using a threshold of -190 to -30 Hounsfield Units (HU) was used to 770 
characterize each voxel as fat.112  The PAT volume was the sum of all pericardial fat voxels over the 45 771 
mm volume. Using this protocol, inter-class correlations for inter-reader comparisons were previously 772 
shown to be 0.96 for PAT.112 773 
 774 
Imputation  775 
A total of 1,263 African American GENOA participants were genotyped on the Affymetrix Genome-Wide 776 
Human SNP Array 6.0 at the Mayo Clinic in Rochester, Minnesota and an additional 269 were 777 
genotyped using the Illumina Human 1M-Duo BeadChip. Since the sibships for the GENOA study were 778 
identified using hypertensive participants from the ARIC Study as probands, we also obtained 779 
genotypes for 92 additional GENOA participants who were also in the ARIC Study and who could not 780 
be genotyped on either platform using the GENOA blood sample. Genotyping for the ARIC study was 781 
carried out at the Broad Institute on the Affymetrix 6.0 platform. For all genotyping platforms used, 782 
samples and SNPs with a call rate <95% were removed. Samples demonstrating sex mismatch, 783 
duplicate samples, and samples with low identity-by-state with all other samples were also removed.  784 
Imputation was performed with the single-step approach implemented in Markov Chain Haplotyper 785 
(MaCH) 1.0.16.114  The reference panel was composed of the HapMap phased haplotypes (release 22) 786 
from 60 unrelated CEU and 60 unrelated YRI samples. Imputation was performed separately for 787 
participants genotyped on the Affymetrix 6.0 as part of the GENOA study, participants genotyped on 788 
the Illumina Human 1M-Duo BeadChip, and participants genotyped on the Affymetrix 6.0 as part of the 789 
ARIC Study. Since only a small number of directly genotyped SNPs overlap on the Affymetrix and 790 
Illumina platforms, imputed dosages were used for all.  791 
 792 
Statistical analysis  793 
We performed analyses with MMAP (Mixed Models Analysis for Pedigrees and Populations).115  We 794 
adjusted for population stratification with the first four principal components estimated using 795 
EIGENSTRAT.107 796 
 797 
HABC - Health Aging and Body Composition study 798 
The Health ABC study is a prospective cohort study investigating the associations between body 799 
composition, weight-related health conditions, and incident functional limitation in older adults. Health 800 
ABC enrolled well-functioning, community-dwelling black (n = 1281) and white (n = 1794) men and 801 
women aged 70–79 years between April 1997 and June 1998. Participants were recruited from a 802 
random sample of white and all black Medicare eligible residents in the Pittsburgh, PA, and Memphis, 803 
TN, metropolitan areas. Participants have undergone annual exams and semi-annual phone interviews. 804 
The current study sample consists of 1559 white participants who attended the second exam in 1998–805 
1999 with available genotyping and SAT/VAT data.  All protocols and analyses were approved by the 806 
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Institutional Review Board at the University of Pittsburgh, University of Tennessee and the National 807 
Institutes on Aging. 808 
 809 
Regional fat depots were assessed from CT scans obtained in Pittsburgh on a General Electric 9800 810 
Advantage (General Electric, Milwaukee, WI) and in Memphis on a Siemens Somatron Plus 4 811 
(Siemens, Erlangen, Germany) or Picker PQ2000S (Marconi Medical Systems, Cleveland, OH). A 812 
single axial scan (140 kVp, 300 to 360 mAs, 10-mm thickness) was taken at the disk space between 813 
the fourth and fifth lumbar vertebrae. Images were transferred to the Reading Center at the University 814 
of Colorado Health Sciences Center on optical disc or magnetic tape. Analyses were performed on a 815 
SPARC station II (Sun Microsystems, Mountain View, CA) using IDL development software (RSI 816 
Systems, Boulder, CO). An outline was traced surrounding the abdominal cavity. The adipose tissue 817 
density range was determined with a bimodal image distribution histogram for each participant. Visceral 818 
fat was defined as the area of all adipose tissue within the abdominal cavity with exclusion of the 819 
muscle region, calculated by multiplying the number of pixels within this range by a single pixel area. 820 
Abdominal subcutaneous fat was defined as the difference in the area between the entire adipose 821 
tissue in the scan and visceral fat. To assess the reproducibility of these measurements, 5% of the data 822 
was re-read in a blinded fashion. The intra-class correlation coefficients of reliability ranged from 0.93 to 823 
1.000. 824 
 825 
Genotyping and imputation. 826 
Genomic DNA was extracted from buffy coat collected using PUREGENE DNA Purification Kit during 827 
the baseline exam. Genotyping was performed by the Center for Inherited Disease Research (CIDR) 828 
using the Illumina Human1M-Duo BeadChip system. Samples were excluded from the dataset for the 829 
reasons of sample failure, genotypic sex mismatch, and first-degree relative of an included individual 830 
based on genotype data. Genotyping was successful for 1,151,215 SNPs in 2,802 unrelated individuals 831 
(1663 Caucasians and 1139 African Americans). Imputation was done for the autosomes using the 832 
MACH software version 1.0.16. SNPs with minor allele frequency ≥1%, call rate ≥97% and HWE p≥10-833 
6 were used for imputation. HapMap II phased haplotypes were used as reference panels. For EAs, 834 
genotypes were available on 914,263 high quality SNPs for imputation based on the HapMap CEPH 835 
reference panel (release 22, build 36). A total of 2,543,887 in EAs are available for analysis. 836 
 837 
Statistical analysis. 838 
We performed linear regression modeling for SAT, VAT, and the VAT/SAT ratio. We observed 839 
association with the first principal components estimated using EIGENSTRAT;107 this was accounted 840 
for in our analyses. 841 
 842 
JHS - Jackson Heart Study 843 
The Jackson Heart Study is a single-site, prospective cohort study of the risk factors and causes of 844 
cardiovascular disease in adult African Americans. A probability sample of 5,301 African Americans, 21 845 
to 84 years of age, residing in the three counties surrounding Jackson, MS, were recruited and 846 
examined at baseline (2000–2004) by trained and certified technicians according to standardized 847 
protocols. For all participants, the clinic visit included physical examination, anthropometry, survey of 848 
medical history and of cardiovascular risk factors, and collection of blood and urine for biological 849 
variables. Clinic visits and interviews occurred approximately every three years. Annual follow-up 850 
interviews and cohort surveillance are ongoing.   All protocols and analyses were approved by the 851 
Institutional Review Board at Jackson Heart Study: Jackson State University, University of Mississippi 852 
Medical Center, and Tougaloo College             853 
 854 
JHS Computed Tomography Protocol 855 
CT-imaging slices of the chest and lower abdomen (L3-S1) were obtained by 16 slice multi-detector CT 856 
(GE Healthcare Lightspeed 16 Pro, Waukeshau, Wisconsin) during Exam 2 at the Jackson Medical 857 
Mall.  Imaging consisted of a scout, prospective ECG gated series through the chest/heart and a helical 858 
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scan through the lower abdomen from L3-S1. The participants were scanned while lying on a 859 
rectangular 3 sample calcium calibration QCT Phantom (Image Analysis, Columbia, KY) long enough to 860 
extend from the top of the chest to the sacrum. The long axis of the QCT phantom paralleled the 861 
participant’s spine. The phantom is made from tissue equivalent plastic and contains rods of 862 
hydroxyapatite of known radiographic densities: 0 for water, and 75 and 150 hydroxyapatite.  Use of the 863 
QCT Phantom permits quantitative assessment of scans between patients (an internal standard).  KV 864 
was 120 and gantry speed was 0.40 s.  For participants weighing ≥220 lbs (100 Kg), the tube current 865 
(or mA) was increased by 25% from 400 mA to 500 mA.   Participants received a one-time exposure of 866 
less than 6 mSv. Scans were analyzed centrally at the Wake Forest University School of Health 867 
Sciences (PI J. Jeffrey Carr).  Calcified plaque in the coronary arteries and abdominal aorta were 868 
viewed and scored using a TeraRecon Aquarius Workstation (TeraRecon, Inc., San Mateo, CA).  869 
 870 
Volumetric adipose tissue imaging  871 
Briefly, abdominal fat volumes were measured from a 50 cm DFOV CT scan series with a 2.5 mm slice 872 
collimation to cover 60 mm (24 slices each 2.5 mm thick) of abdomen from L3 to S1. Scanning was 873 
centered on the lumbar disk space centered at L4-L5.112  Pericardial adipose tissue was measured from 874 
a 35 cm DFOV CT scan series of the heart with a 2.5 mm slice collimation starting 15 mm above and 875 
ending 30 mm below the superior extent of the left main coronary artery for coverage of 45 mm (18 876 
slices each 2.5 mm thick) along the head-foot (z-axis) of the participant.112 877 
 878 
Abdominal adipose tissue measurements  879 
Subcutaneous and visceral adipose tissue volumes (SAT and VAT, respectively) were assessed with 880 
volume analysis software (Advantage Windows; GE Healthcare, Waukesha, WI). The abdominal 881 
muscular wall separating the visceral from the subcutaneous compartment was manually traced. Fat 882 
volumes in the different compartments were measured by a semiautomatic segmentation technique. A 883 
tissue attenuation using a threshold of -190 to -30 Hounsfield Units (HU) was used to characterize each 884 
voxel as fat.113  Using this protocol, inter-class correlations for inter-reader comparisons were previously 885 
shown to be 0.95 for VAT and SAT.113 886 
 887 
MESA - Multi-Ethnic Study of Atherosclerosis 888 
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical 889 
cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular 890 
disease or progression of the subclinical disease. MESA consisted of a diverse, population-based 891 
sample of an initial 6,814 asymptomatic men and women aged 45-84. 38 percent of the recruited 892 
participants were white, 28 percent African American, 22 percent Hispanic, and 12 percent Asian, 893 
predominantly of Chinese descent. Participants were recruited from six field centers across the United 894 
States: Wake Forest University, Columbia University, Johns Hopkins University, University of 895 
Minnesota, Northwestern University and University of California - Los Angeles.116  All protocols and 896 
analyses were approved by the Institutional Review Boards of each participating university. Each 897 
participant received an extensive physical exam and determination of coronary calcification, ventricular 898 
mass and function, flow-mediated endothelial vasodilation, carotid intimal-medial wall thickness and 899 
presence of echogenic lucencies in the carotid artery, lower extremity vascular insufficiency, arterial 900 
wave forms, electrocardiographic (ECG) measures, standard coronary risk factors, sociodemographic 901 
factors, lifestyle factors, and psychosocial factors. Selected repetition of subclinical disease measures 902 
and risk factors at follow-up visits allowed study of the progression of disease. Participants are being 903 
followed for identification and characterization of cardiovascular disease events, including acute 904 
myocardial infarction and other forms of coronary heart disease (CHD), stroke, and congestive heart 905 
failure; for cardiovascular disease interventions; and for mortality. The first examination took place over 906 
two years, from July 2000 - July 2002. It was followed by four examination periods that were 17-20 907 
months in length. Participants have been contacted every 9 to 12 months throughout the study to 908 
assess clinical morbidity and mortality.  909 
 910 
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For the Abdominal Body Composition, Inflammation, and Cardiovascular disease ancillary study, a 911 
subset of the baseline MESA cohort had abdominal CT scans performed at exams 2 or 3.  Of these, a 912 
small number were rescanned at exam 4. As part of the MESA Body Composition ancillary study, 913 
selected abdominal slices from these scans were processed using MIPAV 4.1.2 software (provided by 914 
the NIH) that produced areas of fat, lean, and total tissue measured in square centimeters, as well as 915 
densities expressed in Hounsfield units (HU), for each specific tissue type and anatomic structure. The 916 
structures were defined as total abdomen area of interest (AOI), subcutaneous AOI and visceral AOI, 917 
plus 4 sets of muscles consisting of the right and left psoas, right and left rectus abdominis, right and 918 
left paraspinal muscle group, and right and left oblique muscle group.  For this ancillary study, fat tissue 919 
was identified as being between -190 and -30 Hounsfield units (HU). Lean tissue was identified as 920 
being between 0 and 100 HU. Densities outside of these 2 ranges were labeled as undefined tissue 921 
type.  922 
 923 
Measurement of pericardial fat volume by computed tomography (CT) 924 
Consenting participants underwent CT scanning of the chest at Exam 1 (2000-2002) in MESA.  925 
Pericardial fat was measured in 18 2.5-mm slices, from 1.5 cm above to 3.0 cm below the superior 926 
extent of the left main coronary artery, using Volume Analysis software (GE Healthcare, Waukesha, 927 
WI). The anterior border of the volume was defined by the chest wall and the posterior border by the 928 
aorta and the bronchus. This volume includes the pericardial fat located around the proximal coronary 929 
arteries. Tissue with attenuation of -190 to -30 Hounsfield units was defined as fat. The pericardial fat 930 
volume was the sum of all voxels containing fat. The intrareader reproducibility was excellent in both 931 
studies (intraclass correlation coefficients, 0.99 in MESA). This measure of pericardial fat volume was 932 
highly correlated with total volume of pericardial fat as measured in the Diabetes Heart Study 933 
(correlation coefficient 0.93). All suitable CT scans in MESA were read for pericardial fat. 934 
 935 
Imputation  936 
IMPUTE version 2.1.0 was used to perform imputation for the MESA SHARe Caucasian participants 937 
(chromosomes 1-22) using HapMap Phase I and II - CEU as the reference panel (release #24 - NCBI 938 
Build 36 (dbSNP b126)). We imputed genotypes to nearly 2.5 million HapMap SNPs; further details are 939 
presented in Supplementary Table 1 Statistical analysis We performed linear regression modeling to 940 
account for covariates including age, gender, study sites, smoking status and PCs (SNPTEST). 941 
 942 
MRCOB/TOPS - Metabolic Risk Complications of Obesity Genes/Take Off Pounds Sensibly, Inc 943 
In 1993, the MRC-OB Family Study began with the initial recruitment based on the TOPS (Take Off 944 
Pounds Sensibly, Inc) membership (620 families of 3,007 Caucasian individuals). The design of 945 
recruitment and phenotype ascertainment has been described previously.117 Beginning in year 1998, 946 
506 individuals of 39 families were selected for phenotyping for a set of refined MetS traits that reflect 947 
not only clinical outcomes but also the biologic precursors including measurement of total body fat by 948 
DXA, measurement of abdominal subcutaneous and visceral fat masses (focus of this study) and acute 949 
insulin response by Minimal Model Analysis.118 950 
 951 
Measurement of Body Fat Distribution by Computerized Tomography (CT) 952 
Abdominal imaging to quantitate abdominal fat compartments119-121 was performed using a General 953 
Electric (Waukesha, Wl) 1.5-T whole-body MRI system using a GE Highspeed Advantage CT Scanner 954 
(GE Medical Systems, Waukesha Wl). Scans were performed using a scan circle diameter of 48cm. 955 
Contiguous axial slices of 3 mm were obtained from the superior to inferior surfaces of the 3rd (L3) 956 
lumbar vertebra. The plane of the slices was parallel to the superior and inferior surfaces of the 957 
vertebra. lmages were generated at 120 kV, one-second scanning and 150-240 mA. lmages were 958 
displayed on a 512 x 512 matrix with CT numbers ranging from -1000 to +1000 (0 representing water). 959 
ln addition, a trabecular bone constancy phantom consisting of three sections with known densities, 960 
was placed on the subject's abdomen during the abdominal scans. 961 
 962 
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lmage Analysis. Phenotypes obtained from CT scans include total abdominal visceral fat volume (cmt), 963 
total abdominal subcutaneous fat volume (cmt) and total abdominal fat volume (cmt). The 964 
subcutaneous and intra-abdominal adipose tissue areas were differentiated by encircling the abdominal 965 
muscular wall. The number of volume elements in the scan containing fat was determined by 966 
thresholding techniques.121,122  Computer software delineates tissue areas, from which quantitative 967 
estimates of the amounts of adipose tissue, muscle, or bone can be estimated.  968 
 969 
SNP Genotyping and Data Cleaning 970 
Genomic DNA was extracted and prepared from whole blood using commercial kits (Puregene, 971 
Minneapolis, MN). Genome-wide SNP genotyping was performed using Affymetrix Genome-Wide 972 
Human SNP 6.0 arrays and SNP calls were generated by Genotype Console 3.2. Individuals with fewer 973 
than 95% of all available markers called were excluded. 869,222 autosomal SNPs were prepared by 974 
Preswalk and checked for Mendelian consistency with SimWalk2. A SNP was eliminated if: 1) fewer 975 
than 95% of the cohort were typed successfully; 2) the SNP was monoallelic; 3) the SNP had more 976 
than two alleles; 4) fewer than five copies of the SNP existed in the current study cohort. Hardy-977 
Weinberg equilibrium (HWE) was tested for each SNP using SOLAR;1 SNPs with excessive deviation 978 
from HWE (p < 10-8) were excluded. Individuals who had missing data for individual SNPs had missing 979 
data imputed with MERLIN.123  980 
 981 
Statistical analysis 982 
Imputation  983 
Annotations for the genotyped SNPs (strand and basepair location) were obtained from the official 984 
annotation files provided by Affymetrix (GenomeWideSNP_6.na30.annot.csv.zip) and used to revert 985 
dosages (see above) back to genotypes (A/B encoded alleles) and to identify SNPs to be flipped to the 986 
+ strand. Then all genotyped individuals were coded as unrelateds and pre-phased into haplotypes 987 
using SHAPEIT.124 Pre-phased haplotypes were then imputed using IMPUTE2,125 a CEU panel, and 988 
windows of 5Mbp across each autosome. Autosomes were re-assembled after the imputation and the 989 
pedigree structure was restored. Using pedigree information, Mendelian inconsistencies in the imputed 990 
alleles were blanked and re-imputed with MERLIN. We expressed imputed genotypes as allelic dosage 991 
(weighted probabilities of number of copies of minor allele as a fractional value on range [0,2]). 992 
 993 
Association tests 994 
Analyses were performed using SOLAR.1 Minor allele dosages were included as covariates in 995 
variance-components mixed models for measured genotype analyses;126 all models incorporated the 996 
random effect of kinship and fixed effects such as age, age2, and smoking. Individual scores from a 997 
principal components analysis of representative SNPs were also included to correct for possible 998 
population stratification.107 For each SNP covariate, maximum likelihood estimates of regression beta 999 
+/- standard error and percent of trait variance explained were obtained, and p-values were obtained 1000 
from likelihood ratio tests against the null hypothesis of no association. 1001 
 1002 
PIVUS - Prospective Investigation of the Vasculature in Uppsala Seniors 1003 
PIVUS is a community-based cohort of individuals living in Uppsala, Sweden with a primary aim of 1004 
investigating vascular function in the elderly.  All protocols and analyses were approved by the Ethics 1005 
Committee of the University of Uppsala, and all participants provided informed consent.   For cohort 1006 
specific study protcols, please refer to: Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of 1007 
three different methods to evaluate endothelium-dependent vasodilation in the elderly. The Prospective 1008 
Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Arterioscler Thromb Vasc Biol. 1009 
2005; 25:2368-75.127,128  1010 
 1011 
SHIP-2 and SHIPTREND - Study of Health in Pomerania 1012 
The Study of Health in Pomerania (SHIP) is a population-based project in West Pomerania, the north-1013 
east area of Germany.129,130 A sample from the population aged 20 to 79 years was drawn from 1014 
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population registries. First, the three cities of the region (with 17,076 to 65,977 inhabitants) and the 12 1015 
towns (with 1,516 to 3,044 inhabitants) were selected. Then 17 out of 97 smaller towns (with less than 1016 
1,500 inhabitants) were drawn at random. From each of the selected communities, subjects were 1017 
drawn at random, proportional to the population size of each community stratified by age and gender. 1018 
Only individuals with German citizenship and main residency in the study area were included. Finally, 1019 
7,008 subjects were sampled, with 292 persons of each gender in each of the twelve five-year age 1020 
strata. In order to minimize drop-outs by migration or death, subjects were selected in two waves. The 1021 
net sample (without migrated or deceased persons) comprised 6,267 eligible subjects. Selected 1022 
persons received a maximum of three written invitations. In case of non-response, letters were followed 1023 
by a phone call or by home visits if contact by phone was not possible. The SHIP population finally 1024 
comprised 4,308 participants (corresponding to a final response of 68.8%). 1025 
 1026 
The SHIP-TREND is a longitudinal population based cohort study assessing the prevalence and 1027 
incidence of common, population relevant diseases and their risk factors. Baseline examinations 1028 
started in 2008 and were finished in 2012.121 The sample was drawn randomly from population 1029 
registries. The study region is essentially the same as the study region of the initial SHIP cohort.129,130  1030 
The medical ethics committee of the University of Greifswald approved the study protocol. Oral and 1031 
written informed consents were obtained from each of the study participants. 1032 
 1033 
The SHIP samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. 1034 
Hybridisation of genomic DNA was done in accordance with the manufacturer’s standard 1035 
recommendations. The genetic data analysis workflow was created using the Software InforSense. 1036 
Genetic data were stored in a Caché database (InterSystems). Genotypes were determined using the 1037 
Birdseed2 clustering algorithm. For quality control purposes, several control samples were added. On 1038 
the chip level, only subjects with a genotyping rate on QC probesets (QC callrate) of at least 86% were 1039 
included. Finally, all arrays had a sample callrate > 92%. The overall genotyping efficiency of the GWA 1040 
was 98.55 %. Imputation of genotypes in SHIP was performed with the software IMPUTE v0.5.0 based 1041 
on HapMap II. 1042 
 1043 
A subset of the SHIP-TREND samples was genotyped using the Illumina Human Omni 2.5 array. 1044 
Hybridisation of genomic DNA was done in accordance with the manufacturer’s standard 1045 
recommendations at the Helmholtz Zentrum München. The genetic data analysis workflow was created 1046 
using the Software InforSense. Genetic data were stored in a Caché database (InterSystems). 1047 
Genotypes were determined using the GenomeStudio Genotyping Module v1.0 (GenCall algorithm). All 1048 
986 arrays included had a genotyping rate of at least 94%. The overall genotyping efficiency of the 1049 
GWA was 99.67 %. Imputation of genotypes in SHIP was performed with the software IMPUTEv2 1050 
based on HapMap II (CEU v22, Build 36). 1051 
1052 
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